



Europäisches
Patentamt

European
Patent Office

Office européen
des brevets

PCT/EP 00 / 09896

#2

REC'D 05 FEB 2001

WIPO

PCT

EP00/9896

Bescheinigung

Certificate

Attestation

4

Die angehefteten Unterla-
gen stimmen mit der
ursprünglich eingereichten
Fassung der auf dem näch-
sten Blatt bezeichneten
europäischen Patentanmel-
dung überein.

The attached documents
are exact copies of the
European patent application
described on the following
page, as originally filed.

Les documents fixés à
cette attestation sont
conformes à la version
initialement déposée de
la demande de brevet
européen spécifiée à la
page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

00401388.4

**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

Der Präsident des Europäischen Patentamts;
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets
p.o.

I.L.C. HATTEN-HECKMAN

DEN HAAG, DEN
THE HAGUE,
LA HAYE, LE

25/01/01

THIS PAGE BLANK (USPTO)



Europäisches
Patentamt

European
Patent Office

Office européen
des brevets

**Blatt 2 der Bescheinigung
Sheet 2 of the certificate
Page 2 de l'attestation**

Anmeldung Nr.:
Application no.:
Demande n°: 00401388.4

Anmeldetag:
Date of filing:
Date de dépôt: 18/05/00

Anmelder:
Applicant(s):
Demandeur(s):
INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE
F-75341 Paris Cédex 07
FRANCE

Swedish University of Agricultural Sciences Uppsala Biomedical Centre
751 24 Uppsala

SWEDEN
Bezeichnung der Erfindung:
Title of the invention:
Titre de l'invention:

Variants of the gamma chain of AMPK, DNA sequences encoding the same, and uses thereof

In Anspruch genommene Priorität(en) / Priority(ies) claimed / Priorité(s) revendiquée(s)

Staat:
State:
Pays:

Tag:
Date:
Date:

Aktenzeichen:
File no.
Numéro de dépôt:

Internationale Patentklassifikation:
International Patent classification:
Classification internationale des brevets:

/

Am Anmeldetag benannte Vertragsstaaten:
Contracting states designated at date of filing: AT/BE/CH/CY/DE/DK/ES/FI/FR/GB/GR/IE/IT/LI/LU/MC/NL/PT/SE/TR
Etats contractants désignés lors du dépôt:

Bemerkungen:
Remarks:
Remarques:

THIS PAGE BLANK (USPTO)

VARIANTS OF THE GAMMA CHAIN OF AMPK, DNA SEQUENCES
ENCODING THE SAME, AND USES THEREOF.

The present invention relates to new variants of the γ chain of AMP-activated protein kinase (AMPK), to
5 genes encoding said variants and to uses thereof.

AMPK has a key role in regulating the energy metabolism in the eukaryotic cell (HARDIE et al., Annu. Rev. Biochem., 67, 821-855, 1998; KEMP et al., TIBS, 24, 22-25, 1999). Mammalian AMPK is a heterotrimeric complex
10 comprising a catalytic α subunit and two non-catalytic β and γ subunits that regulate the activity of the α subunit. The yeast homologue (denoted SNF1) of this enzyme complex is well characterised; it comprises a catalytic chain (Snf1) corresponding to the mammalian α
15 subunit, and regulatory subunits: Sipl1, Sip2 and Gal83 correspond to the mammalian β subunit, and Snf4 correspond to the mammalian γ subunit. Sequence data show that AMPK homologues exist also in *Caenorhabditis elegans* and *Drosophila*.

20 It has been observed that mutations in yeast SNF1 and SNF4 cause defects in the transcription of glucose-repressed genes, sporulation, thermotolerance, peroxisome biogenesis, and glycogen storage.

In the mammalian cells, AMPK has been proposed
25 to act as a "fuel gauge". It is activated by an increase in the AMP:ATP ratio, resulting from cellular stresses such as heat shock and depletion of glucose and ATP. Activated AMPK turns on ATP-producing pathways (e.g. fatty acid oxidisation) and inhibits ATP-consuming
30 pathways (e.g. fatty acid and cholesterol synthesis), through phosphorylation of the enzymes acetyl-CoA carboxylase and hydroxymethylglutaryl-CoA (HMG-CoA) reductase. It has also been reported to inactivate in vitro glycogen synthase, the key regulatory enzyme of
35 glycogen synthesis, by phosphorylation (HARDIE et al.,

1998, *supra*); however, whether glycogen synthase is a physiological target of AMPK *in vivo* remained unclear.

Several isoforms of the three different AMPK subunits are present in mammals. In humans, *PRKAA1* on human chromosome (HSA) 5p12 and *PRKAA2* on HSA1p31 respectively encode isoforms $\alpha 1$ and $\alpha 2$ of the α subunit, *PRKAB1* on HSA12q24.1 and *PRKAB2* (not yet mapped) respectively encode isoforms $\beta 1$ and $\beta 2$ of the β subunit, and *PRKAG1* on HSA12q13.1 and *PRKAG2* on HSA7q35-q36 respectively encode isoforms $\gamma 1$ and $\gamma 2$ of the γ subunit (OMIM database, <http://www.ncbi.nlm.nih.gov/omim/>, July 1999). HARDIE et al., [1998, *supra*] also mention the existence of a third isoform ($\gamma 3$) of the γ subunit of AMPK but do not provide any information about it. Analysis of the sequences of these γ subunits shows that they are essentially composed of four cystathione β synthase (CBS) domains whose function is unknown. No phenotypic effect resulting from a mutation in either of the AMPK subunits has yet been documented.

On the other hand, it has been observed that most Hampshire pigs have a high intramuscular glycogen concentration. In these pigs, glycogenolysis which occurs after slaughtering leads to an important decrease of the pH, resulting in acid meat having a reduced water-holding capacity and giving a reduced yield of cured cooked ham.

The locus (named *RN*) associated with high muscular content of glycogen was first identified by family segregation analysis of phenotypic data from Hampshire pigs (LE ROY et al., Genet. Res., 55, 33-40, 1990). A fully dominant allele, *RN*, correlated with high glycogen content occurs at a high frequency in most Hampshire populations while pigs from other breeds are assumed to be homozygous for the normal, recessive *rn*⁺ allele. Subsequent studies showed that *RN* carriers have a large increase (about 70%) of glycogen in skeletal muscle

but not in liver (MONIN et al., in 38th ICOMST, Clermont-Ferrand, FRANCE, 1992).

The large difference in glycogen content between RN⁻ and rn⁺ pigs leads to marked differences in meat quality and technological yield (ENFÄLT et al., J. Anim. Sci., 75, 2924-2935, 1997). The RN⁻ allele is therefore of considerable economical significance in the pig industry and most breeding companies would like to reduce or eliminate this dominant mutation.

The RN phenotype can be determined by measuring the glycolytic potential in muscle biopsies from live animals, or after slaughter (MONIN et al., Meat Science, 13, 49-63, 1985). However, this method has severe limitations for application in practical breeding programs. The accuracy of the test is not 100%: as there is some overlap in the phenotypic distribution of RN⁻ and rn⁺, the test is not able to distinguish RN⁻/RN⁻ homozygotes and RN⁻/rn⁺ heterozygotes. Further, the sampling of muscle biopsies on live animals is invasive and costly.

Thus, there is a strong need for the development of a simple diagnostic DNA test for the RN locus. Moreover, the dramatic phenotypic effect of the RN gene in pigs implies that this gene has an important role in the regulation of carbohydrate metabolism in skeletal muscle in other vertebrates, in particular mammals.

Skeletal muscle and liver are the two major reservoirs of glycogen in mammals and the observation of an increased muscular glycogen while liver glycogen is normal suggests that the RN⁻ phenotype maybe due to a mutation in a gene expressed in muscle but not in liver. The inventors have previously reported that the RN gene is located on pig chromosome 15 (MILAN et al., Mamm. Genome, 7, 47-51, 1996; MARIANI et al., Mamm. Genome, 7, 52-54, 1996; LOOFT et al., Genetics Selection Evolution, 28, 437-442, 1996). They have now discovered that the RN

allele is associated with a non-conservative mutation in a gene encoding a new muscle-specific isoform of the AMP-activated protein kinase (AMPK) γ chain.

The various aspects of the present invention are based upon the discovery and characterisation of this mutation and the identification and isolation of the mutant gene.

According to the invention it is shown that a mutation in a γ chain of AMPK results in an altered regulation of carbohydrate metabolism, demonstrating that AMPK is an essential component of said metabolism. It is also provided a nucleic acid sequence encoding a muscle-specific isoform of the γ chain of AMPK. Thus it is provided means to regulate carbohydrate metabolism, more specifically to detect and/or correct potential or actual dysfunctions of the regulation of carbohydrate metabolism, in particular in skeletal muscle.

The invention provides a polypeptide comprising an amino acid sequence having at least 70% identity or at least 85% similarity, preferably 80% identity or at least 90% similarity, more preferably at least 90% identity or at least 95% similarity, and still more preferably at least 95% identity or at least 99% similarity, with the polypeptide SEQ ID NO: 2. The invention also provides an isolated nucleic acid sequence encoding said polypeptide, as well as the complement of said nucleic acid sequence.

Said polypeptide represents a new muscle-specific isoform of the γ chain of AMPK, and will also be hereinafter referred as Prkag3; the gene encoding said polypeptide will also be hereinafter referred as PRKAG3.

"Identity" of a sequence with a reference sequence refers to the percent of residues that are the same when the two sequences are aligned for maximum correspondence between residues positions. A polypeptide having an amino acid sequence having at least X% identity

with a reference sequence is defined herein as a polypeptide whose sequence may include up to 100-X amino acid alterations per each 100 amino acids of the reference amino acid sequence. Amino acids alterations
5 include deletion, substitution or insertion of consecutive or scattered amino acid residues in the reference sequence.

"Similarity" of a sequence with a reference sequence refers to the percent of residues that are the
10 same or only differ by conservative amino acid substitutions when the two sequences are aligned for maximum correspondence between residues positions. A conservative amino acid substitution is defined as the substitution of an amino acid residue for another amino
15 acid residue with similar chemical properties (e.g. size, charge or polarity), which generally does not change the functional properties of the protein. A polypeptide having an amino acid sequence having at least X% similarity with a reference sequence is defined herein as
20 a polypeptide whose sequence may include up to (100-X) non-conservative amino acid alterations per each 100 amino acids of the reference amino acid sequence. Non-conservative amino acids alterations include deletion, insertion, or non-conservative substitution of
25 consecutive or scattered amino acid residues in the reference sequence.

For instance, searching the "GenBank nr" database using BLASTp (ALTSCHUL et al., Nucleic Acids Res., 25, 3389-3402, 1997) with default settings and the
30 whole sequence SEQ ID NO: 2 as a query, the higher percents of identity or similarity with SEQ ID NO: 2 were found for:

- γ 1 subunit of human AMPK: 65% identity or 82% similarity (score: 399);
- 35 - γ 1 subunit of rat AMPK: 65% identity or 82% similarity (score: 399);

- γ 1 subunit of murine AMPK: 64% identity or 80% similarity (score: 390);

- γ subunit of Drosophila AMPK: 53% identity or 75% similarity (score: 332);

5 - Yeast Snf4: 33% identity or 56% similarity (score: 173).

Polypeptides of the invention include for instance any polypeptide (whether natural, synthetic, semi-synthetic, or recombinant) from any vertebrate
10 species, more specifically from birds, such as poultry, or mammals, including bovine, ovine, porcine, murine, equine, and human, and comprising, or consisting of, the amino acid sequence of either:

- a functional Prkag3; or

15 - a functionally altered mutant of Prkag3.

"Functional" refers to a protein having a normal biological activity. Such a protein may comprise silent mutations inducing no substantial change in its activity, and having no noticeable phenotypic effects.

20 Non limitative examples of functional Prkag3 are:

- a porcine Prkag3 comprising at least the sequence represented in the enclosed sequence listing under SEQ ID NO: 2;

25 - a human Prkag3 comprising at least the sequence represented in the enclosed sequence listing under SEQ ID NO: 4;

30 - a V40I variant of Prkag3 resulting from the substitution of a valine residue in position 40 of SEQ ID NO: 2 or SEQ ID NO: 4 by an isoleucine residue.

The invention also includes splice variants of Prkag3: for instance, the nucleotide sequence and amino-acid sequence of 2 splice variants of porcine Prkag3 are represented in figure 7 (7a: nucleotide sequence; 7b:
35 amino-acid sequence) and 8 (8a: nucleotide sequence; 8b: amino-acid sequence).

A "functionally altered mutant" of a protein comprises one or several mutations inducing a substantial change in its activity. Such mutations include in particular deletions, insertions, or non-conservative substitutions of amino acid residues in a domain essential for the biological activity of said protein. They may result for instance in a partial or total loss of activity, or conversely in an increase of activity, or in an impairment of the response to regulatory effectors.

5 A non-limitative example of a functionally altered mutant of Prkag3 is the R41Q variant resulting from the non-conservative substitution of an arginine residue by a glutamine residue in position 41. This non-conservative substitution occurs inside a portion of the first CBS domain that is highly conserved between Prkag3 and the

10 previously known isoforms of the γ subunit of AMPK.

15

Residue numbers for Prkag3 refer to the amino acid numbering of SEQ ID NO: 2 or SEQ ID NO: 4. Alignment of human and porcine Prkag3 sequences with previously known $\gamma 1$ and $\gamma 2$ isoforms is shown in Figure 3.

20

The invention also provides mutants of Prkag3 which may for instance be obtained by deletion of part of a Prkag3 polypeptide. Said mutants are generally functionally altered. They may have an identity with the overall Prkag3 sequence lower than 70%. However, the identity of the non-deleted sequences of said mutants, when aligned with the corresponding Prkag3 sequences should remain higher than 70%. Said mutants may for instance result from the expression of nucleic acid sequences obtained by deletion or insertion of a nucleic acid segment, or by a punctual mutation introducing a nonsense codon, in a nucleic acid sequence encoding a functional Prkag3.

25

30

The invention also provides a functionally altered mutant of a γ subunit of AMPK, wherein said mutant comprises at least one mutation responsible for said

35

functional alteration located within the first CBS domain, and preferably within the region thereof aligned with the region spanning from residue 30 to residue 50 of SEQ ID NO:2. Said mutation may result from the insertion, deletion, and/or non-conservative substitution of one amino-acid or of several amino-acids, adjacent or not. More preferably the mutation is located within the region aligned with the region spanning from residue 35 to residue 45 of SEQ ID NO:2, for instance within the region spanning from residue 65 to residue 75 of the γ 1 isoform. According to a particular embodiment, said mutation is a non-conservative substitution, preferably a R \rightarrow Q substitution. Advantageously, the mutation is located at a residue corresponding to residue 41 of SEQ ID NO:2, for instance at residue 70 of the γ 1 isoform.

The invention also provides a heterotrimeric AMPK wherein the γ subunit consists of a polypeptide of the invention.

The invention also provides isolated nucleic acid sequences encoding any of the above-defined functional or functionally altered Prkag3 or functionally altered mutants of a γ subunit of AMPK, and nucleic acid sequences complementary of any one of these nucleic acid sequences.

This includes particularly any isolated nucleic acid having the sequence of any of the naturally occurring alleles of a *PRKAG3* gene, as well as any isolated nucleic acid having the sequence of an artificial mutant of a *PRKAG3* gene, provided that said nucleic acid does not consist of the EST GENBANK AA178898.

This also includes any isolated nucleic acid having the sequence of a natural or artificial mutant of a *PRKAG1* or a *PRKAG2* gene, wherein said mutant encodes a functionally altered γ 1 or γ 2 subunit of AMPK as defined above.

Nucleic acid sequences of the invention may be obtained by the well-known methods of recombinant DNA technology and/or of chemical DNA synthesis. These methods also allow to introduce the desired mutations in
5 a naturally occurring DNA sequence.

Examples of nucleic acid sequences encoding naturally occurring alleles of a *PRKAG3* gene are SEQ ID NO: 1, which encodes a naturally occurring allele of the porcine gene and SEQ ID NO: 3, which encodes a
10 naturally occurring allele of the human gene. They may be used to generate probes allowing the isolation of *PRKAG3* from other species or of other allelic forms of *PRKAG3* from a same species, by screening a library of genomic DNA or of cDNA.

15 The invention also includes genomic DNA sequences from any vertebrate species, more specifically from birds, such as poultry, or mammals, including in particular bovine, ovine, porcine, murine, equine, and human, comprising at least a portion of a nucleic acid
20 sequence encoding a polypeptide of the invention, preferably a portion of a *PRKAG3* gene, and up to 500 kb, preferably up to 100 kb of a 3' and/or of a 5' adjacent genomic sequence.

Such genomic DNA sequences may be obtained by
25 methods known in the art, for instance by extension of a nucleic acid sequence encoding a polypeptide of the invention, employing a method such as restriction-site PCR (SARKAR *et al.*, PCR Methods Applic., 2, 318-322, 1993), inverse PCR (TRIGLIA *et al.*, Nucleic Acids Res.,
30 16, 8186, 1988) using divergent primers based on a *Prkag3* coding region, capture PCR (LAGERSTROM *et al.*, PCR Methods Applic., 1, 111-119, 1991), or the like.

The invention also includes specific fragments of a nucleic acid sequence encoding a polypeptide of the
35 invention, or of a genomic DNA sequence of the invention as well as nucleic acid fragments specifically

hybridising therewith. Preferably these fragments are at least 15bp long, more preferably at least 20bp long.

"Specific fragments" refers to nucleotidic sequences that are found only in the nucleic acids sequences encoding a polypeptide of the invention, and are not found in nucleic acids sequences encoding related polypeptides of the prior art. This excludes the nucleic acid fragments that consist of a sequence shared with one of the known *PRKAG1* or *PRKAG2* genes.

"Specifically hybridising fragments" refers to nucleic acid fragments which can hybridise, under stringent conditions, only with nucleic acid sequences encoding a polypeptide of the invention, without hybridising with nucleic acid sequences encoding related polypeptides of the prior art. This excludes the nucleic acid fragments that consist of the complement of a sequence shared with one of the known *PRKAG1* or *PRKAG2* genes.

Nucleic acid fragments that consist of the EST GENBANK AA178898 or the complement thereof are also excluded.

Said specific or specifically hybridising nucleic acid fragments may for example be used as primers or probes or for detecting and/or amplifying a nucleic acid sequence encoding a polypeptide of the invention. The invention encompasses set of primers comprising at least one primer consisting of a specific or specifically hybridising nucleic acid fragment as defined above.

The invention also provides recombinant vectors comprising a nucleic acid sequence encoding a polypeptide of the invention. Vectors of the invention are preferably expression vectors, wherein a sequence encoding a polypeptide of the invention is placed under control of appropriate transcriptional and translational control elements. These vectors may be obtained and

introduced in a host cell by the well-known recombinant DNA and genetic engineering techniques.

The invention also comprises a prokaryotic or eukaryotic host cell transformed by a vector of the invention, preferably an expression vector.

A polypeptide of the invention may be obtained by culturing the host cell containing an expression vector comprising a nucleic acid sequence encoding said polypeptide, under conditions suitable for the expression of the polypeptide, and recovering the polypeptide from the host cell culture.

A heterotrimeric AMPK wherein the γ subunit consists of a polypeptide of the invention may be obtained by expressing, together or separately, a nucleic acid sequence encoding a polypeptide of the invention, a nucleic acid sequence encoding an α subunit, and a nucleic acid sequence encoding a β subunit, and reconstituting the heterotrimer.

The polypeptides thus obtained, or immunogenic fragments thereof may be used to prepare antibodies, employing methods well known in the art. Antibodies directed against the whole Prkag3 polypeptide and able to recognise any variant thereof may thus be obtained. Antibodies directed against a specific epitope of a particular variant (functional or not) of Prkag3 or antibodies directed against a specific epitope of a functionally altered mutant having a mutation in the first CBS domain of a γ subunit of AMPK, and able to recognise said variant or functionally altered mutant may also be obtained.

As shown herein, mutations in a γ subunit of AMPK, and particularly mutations in the first CBS domain of a γ subunit of AMPK are likely to cause disorders in the energy metabolism (e.g. diabetes, obesity) in vertebrates, including humans. Further, mutations in the first CBS domain or other parts of the PRKAG3 gene are

likely to cause disorders in the muscular metabolism leading to diseases such as myopathy, diabetes and cardiovascular diseases.

The present invention provides means for
5 detecting and correcting said disorders.

More specifically, the present invention is directed to methods that utilise the nucleic acid sequences and/or polypeptidic sequences of the invention for the diagnostic evaluation, genetic testing and
10 prognosis of a metabolic disorder.

For example, the invention provides methods for diagnosing of metabolic disorders, more specifically carbohydrate metabolism disorders, and preferably disorders correlated with an altered, in particular an
15 excessive, glycogen accumulation in the cells, resulting from a mutation in a gene encoding a γ subunit of AMPK, wherein said methods comprise detecting and/or measuring the expression of a functionally altered *PRKAG3* gene, or of a functionally altered mutant of a γ subunit of AMPK
20 having a mutation within the first CBS domain in a nucleic acid sample obtained from a vertebrate, or detecting a mutation in the *PRKAG3* gene or in a sequence encoding the first CBS domain of a γ subunit of AMPK in the genome of a vertebrate suspected of having such a
25 disorder.

According to a preferred embodiment of the invention, the disorder is correlated with an altered, in particular an excessive, glycogen accumulation in the muscular cells and results from the expression of a
30 functionally altered *PRKAG3* gene.

The expression of a functionally altered *Prkag3*, or of a functionally altered mutant of a γ subunit of AMPK having a mutation within the first CBS domain may be detected or measured using either polyclonal or
35 monoclonal antibodies specific for the functionally altered polypeptides of the invention, as defined above.

Appropriate methods are known in the art. They include for instance enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and fluorescence activated cell sorting (FACS).

5 The nucleotide sequences of the invention may be used for detecting mutations in the *PRKAG3* gene or in a sequence encoding the first CBS domain of a γ subunit of AMPK, by detection of differences in gene sequences or in adjacent sequences between normal, carrier, or affected
10 individuals.

The invention provides a process for detecting a mutation in the *PRKAG3* gene or in a sequence encoding the first CBS domain of a γ subunit of AMPK wherein said process comprises:

- 15 - obtaining a nucleic acid sample from a vertebrate;
- checking the presence in said nucleic acid sample of a nucleic acid sequence encoding a mutant *Prkag3*, or a mutant of a γ subunit of AMPK having a mutation within the first CBS domain, as defined above.

20 According to a preferred embodiment of the invention there is provided a method for detecting a nucleic acid sequence comprising a mutation in the *PRKAG3* gene or in a sequence encoding the first CBS domain of a γ subunit of AMPK wherein said process comprises:

- 25 - obtaining a nucleic acid sample from a vertebrate;
- contacting said nucleic acid sample with a nucleic acid probe obtained from a nucleic acid of the invention and spanning said mutation, under conditions of specific hybridisation between said probe and the mutant
30 sequence to be detected;
- detecting the hybridisation complex.

Preferably, the process of the invention further comprises, prior to hybridisation, PCR amplification from the nucleic acid sample, of a sequence
35 comprising at least the portion of the *PRKAG3* sequence or

of the sequence encoding the first CBS domain of the γ subunit of AMPK wherein the mutation is to be detected.

Methods allowing the specific hybridisation of a probe only with a perfectly matching complementary
5 sequence, and useful for the detection of punctual mutations are known in the art. They include for instance Allele Specific PCR (GIBBS, Nucleic Acid Res., 17, 2427-2448, 1989), Allele Specific Oligonucleotide Screening (SAIKI et al., Nature, 324, 163-166, 1986), and the like.

10 A mutation in the *PRKAG3* gene may also be detected through detection of polymorphic markers closely linked to said mutation.

The invention also provides means for identifying said polymorphic markers, and more
15 specifically polymorphic markers comprised within a genomic DNA sequence comprising at least a portion of a *PRKAG3* gene, and up to 500 kb, preferably 300 kb, more preferably up to 100 kb of a 3' and/or of a 5' adjacent sequence.

20 Said polymorphic markers may be obtained for instance, by screening a genomic DNA library from a vertebrate with a probe specific for the *PRKAG3* gene, in order to select clones comprising said nucleic acid sequence and flanking chromosomal sequences, and
25 identifying a polymorphic marker in said flanking chromosomal sequences. The allele(s) of a polymorphic marker associated with a given mutant allele of the *PRKAG3* gene may also easily be identified by use of a genomic DNA library from an individual wherein the
30 presence of said mutant allele has previously been detected by hybridisation with a nucleic acid probe of the invention.

Polymorphic markers include for instance, single nucleotide polymorphisms (SNP), microsatellites,
35 insertion/deletion polymorphism and restriction fragment length polymorphism (RFLP). These polymorphic markers may

be identified by comparison of sequences flanking the
PRKAG3 gene obtained from several individuals.
Microsatellites may also be identified by hybridisation
with a nucleic acid probe specific of known
5 microsatellite motifs.

Once a polymorphic marker has been identified,
a DNA segment spanning the polymorphic locus may be
sequenced and a set of primers allowing amplification of
said DNA segment may be designed.

10 The invention also encompasses said DNA
primers.

Detection of a mutation in the PRKAG3 gene may
be performed by obtaining a sample of genomic DNA from a
vertebrate, amplifying a segment of said DNA spanning a
15 polymorphic marker by polymerase chain reaction using a
set of primers of the invention, and detecting in said
amplified DNA the presence of an allele of said
polymorphic marker associated with said mutation.

By way of example, polymorphic markers which
20 may be obtained according to the invention, and DNA
primers allowing the detection of polymorphic markers
closely linked to the RN allele of porcine PRKAG3 gene
are listed in Table 1 hereinafter.

According to a preferred embodiment of the
25 invention, the vertebrate is a mammal, preferably a farm
animal and more preferably a porcine, and the mutation to
be detected produces a functionally altered Prkag3. The
detection of said mutation allows to predict whether said
mammal or the progeny thereof is likely to have a high
30 intramuscular glycogen concentration. An example of such
a mutation produces a functionally altered Prkag3 having
a R41Q substitution.

The present invention also includes kits for
the practice of the methods of the invention. The kits
35 comprise any container which contains at least one
specific fragment of a nucleic acid sequence of the

invention, or at least one nucleic acid fragment able to specifically hybridise with a nucleic acid sequence of the invention. Said nucleic acid fragment may be labelled. The kits may also comprise a set of primers of the invention. They may be used in conjunction with commercially available amplification kits. They may also include positive or negative control reactions or markers, molecular weight size markers for gel electrophoresis, and the like.

Other kits of the invention may include antibodies of the invention, optionally labelled, as well as the appropriate reagents for detecting an antigen-antibody reaction. They may also include positive or negative control reactions or markers.

The invention further provides means for modulating the expression of vertebrate genes encoding a γ subunit of AMPK, and more specifically of the *PRKAG3* gene and/or the synthesis or activity of the products of said genes.

A purified AMPK heterotrimer comprising wild-type or mutant *Prkag3* subunit, or a functionally altered mutant γ subunit having a mutation in the first CBS domain, may be used for screening *in vitro* compounds able to modulate AMPK activity, or to restore altered AMPK activity. This may be done, for instance, by:

- measuring the binding of the compound to said heterotrimer, using for example high-throughput screening methods; or,

- measuring changes in AMPK kinase activity, using for example high-throughput screening methods.

High throughput screening methods are disclosed, for instance, in "High throughput screening: The Discovery of Bioactive Substances", J.P. DEVLIN (Ed), MARCEL DEKKER Inc., New York (1997).

Nucleic acids of the invention may be used for therapeutic purposes. For instance, complementary

molecules or fragments thereof (antisense oligonucleotides) may be used to modulate AMPK activity, more specifically in muscular tissue.

Also, a nucleic acid sequence encoding a functional Prkag3 may be used for restoring a normal AMPK function.

Transformed cells or animal tissues expressing a wild-type or mutant Prkag3, or a functionally altered mutant of a γ subunit of AMPK as defined above, or expressing an AMPK comprising said mutant Prkag3, or said functionally altered mutant of a γ subunit of AMPK, may be used as *in vitro* model for elucidating the mechanism of AMPK activity or for screening compounds able to modulate the expression of AMPK.

The screening may be performed by adding the compound to be tested to the culture medium of said cells or said tissues, and measuring alterations in energy metabolism in said cells or said tissues using methods such as measurements of glucose concentrations (levels), glucose uptake, or changes of the ATP/AMP ratio, glycogen or lipid/protein content.

The invention provides animals transformed with a nucleic acid sequence of the invention.

In one embodiment, said animals are transgenic animals having at least a transgene comprising a nucleic acid of the invention.

In another embodiment, said animals are knockout animals. "Knockout animals" refers to animals whose native or endogenous *PRKAG3* alleles have been inactivated and which produce no functional Prkag3 of their own.

In light of the disclosure of the invention of DNA sequences encoding a wild-type or mutant Prkag3, or a functionally altered mutant of a γ subunit of AMPK, transgenic animals as well as knockout animals may be produced in accordance with techniques known in the art,

for instance by means of *in vivo* homologous recombination.

Suitable methods for the preparation of transgenic or knock-out animals are for instance disclosed in: *Manipulating the Mouse Embryo*, 2nd Ed., by HOGAN et al., Cold Spring Harbor Laboratory Press, 1994; *Transgenic Animal Technology*, edited by C. PINKERT, Academic Press Inc., 1994; *Gene Targeting: A Practical Approach*, edited by A.L. JOYNER, Oxford University Press, 1995; *Strategies in Transgenic Animal Science*, edited by G.M. MONASTERSKY and J.M. ROBL, ASM Press, 1995; *Mouse Genetics: Concepts and Applications*, by Lee M. SILVER, Oxford University Press, 1995.

These animals may be used as models for metabolic diseases and disorders, more specifically for diseases and disorders of glycogen metabolism in muscle. For instance they may be used for screening test molecules. Transgenic animals may thus be used for screening compounds able to modulate AMPK activity. Knockout animals of the invention may be used, in particular, for screening compounds able to modulate energy metabolism, more specifically carbohydrate metabolism, in the absence of functional Prkag3.

The screening may be performed by administering the compound to be tested to the animal, and measuring alterations in energy metabolism in said animal using methods such as glucose tolerance tests, measurements of insulin levels in blood, changes of the ATP/AMP ratio, glycogen or lipid/protein content in tissues and cells.

Transgenic or knock-out farm animals with modified meat characteristics or modified energy metabolism may also be obtained.

The present invention will be further illustrated by the additional description which follows, which refers to examples of obtention and use of nucleic

acids of the invention. It should be understood however that these examples are given only by way of illustration of the invention and do not constitute in any way a limitation thereof.

5 **EXAMPLE 1: ISOLATING THE *PRKAG3* GENE**

We have screened a porcine Bacterial Artificial Chromosome (BAC) library (ROGEL-GAILLARD et al., Cytogenet and Cell Genet, 851, 273-278, 1999) and constructed a contig of overlapping BAC clones across the
10 region of pig chromosome 15 harbouring the *RN* gene. These BAC clones were in turn used to develop new genetic markers in the form of single nucleotide polymorphisms (SNPs) or microsatellites (MS) as described in Table 1 below.

Table 1

	Name of marker	BAC clone	Primer sequences	Size of PCR product (bp)	Marker type ^a	Alleles ^b
1	H3	115B9, 156E6, 361B4, 90A9	F: 5'-GGAATTTCAAGTCAGCCAAC-3' (SEQ ID NO: 5) R: 5'-CTTCAAGACCCGTGCTACT-3' (SEQ ID NO: 6)	114 - 138	MS	114, 126, 128, 132*, 134*, 136, 138
2	MS982H1	982H11	F: 5'-CTGGGAACCTCTATATGCTG-3' (SEQ ID NO: 7) R: 5'-TAGGAAATACAAATCACAG-3' (SEQ ID NO: 8)	114 - 157	MS	114, 140, 142*, 144, 146, 150, 158
3	MS479L3	479L3, 297D7, 852B5, 153B5	F: 5'-CTCCAGCTCACAGGATGACA-3' (SEQ ID NO: 9) R: 5'-GTTCTGCAGCTTAGCATCTATTCC-3' (SEQ ID NO: 10)	150 - 164	MS	150*, 160, 162, 164
4	MS997M3	997F12	F: 5'-GAAGTATCCTGGGCTTCTGA-3' (SEQ ID NO: 11) R: 5'-GTTCTCCAGTTTCCAGACATCCAC-3' (SEQ ID NO: 12)	138 - 160	MS	138, 144, 152, 154, 160*
5	MS482H6	482E7	F: 5'-GCTTCTGTCTGCCCTACTT-3' (SEQ ID NO: 13) R: 5'-GTTCTAAGTCTACTGTAGACAC-3' (SEQ ID NO: 14)	78 - 90	MS	78, 80, 88*, 90
6	MS337H2	808G10, 947E5, 337G11	F: 5'-CCAAGCTGTGGTGGTGAAT-3' (SEQ ID NO: 15) R: 5'-CAGCACACAGTGCCACCTA-3' (SEQ ID NO: 16)	145 - 165	MS	145, 149, 155, 161*, 165*
7	MS127B1	127G6, 134C9	F: 5'-CAAACTCTTCTAGGCGTGT-3' (SEQ ID NO: 17) R: 5'-GTTCTGGAACCTCCATATGCCATGG-3' (SEQ ID NO: 18)	94 - 108	MS	94, 100, 108*, 114
8	CMKAR2	128A3, 337G11, 808G10, 947E7, 1110H12	F: 5'-AGGCTGGATGGTAGGCTTCA-3' (SEQ ID NO: 19) R: 5'-GTCTCGCTCCTGAAGGAAGT-3' (SEQ ID NO: 20)	208	SNP	112A*, 112T; 158A*, 158G 176A*, 176G
9	127G63	127G6, 134C9, 170D7, 1030A5, 1088F2	F: 5'-AGTCACGTGGCCATGCTATC-3' (SEQ ID NO: 21) R: 5'-CTCAACTGGATTGAGTCAGT-3' (SEQ ID NO: 22)	409	SNP	234A*, 234C
10	VIL1		F: 5'-TTGGCGCAACTGTATTCT-3' (SEQ ID NO: 23) R: 5'-AGGCAAGGAAGAGACACAG-3' (SEQ ID NO: 24)	270	SNP	90T, 90G, 120A, 120G, 166C, 166T
11	NRAMP1	315F7, 530A6, 651C12, 1088F2, 1095H3	F: 5'-AGCCGTGGGCATCGTTGG-3' (SEQ ID NO: 25) R: 5'-AGAAGGAGACAGACAGGGCGA-3' (SEQ ID NO: 26)	1300	RFLP (Syl)	1: 100+1200 bp 2: 100+200+1000 bp

^aMS=microsatellite; SNP=single nucleotide polymorphism.

^bMicrosatellite alleles are designated according to the length of the amplified fragment while SNPs are denoted according to the polymorphic nucleotide. Alleles associated with the RV allele are marked with an asterisk.

The new markers were used together with some previously described markers to construct a high-resolution linkage map. Standard linkage analysis using pedigree data comprising about 1,000 informative meioses for segregation at the RN locus made it possible to exclude RN from the region proximal to MS479L3 and distal to microsatellite Sw936. Linkage Disequilibrium (LD) analysis was done with the same markers and a random sample of 68 breeding boars from the Swedish Hampshire population, scored for the RN phenotype by measuring glycogen content in muscle. The results of LD analysis using the DISMULT program (TERWILLIGER, Am. J. Hum. Genet., 56, 777-787, 1995) are shown in Figure 1. They reveal a sharp LD peak around the markers MS127B1 and SNP127G63. These markers appeared to show complete linkage disequilibrium with the RN allele, i.e. RN was associated with a single allele at these two loci. The most simple interpretation of this finding is that the RN mutation arose on a chromosome carrying these alleles and that the two markers are so closely linked to the RN locus that the recombination frequency is close to 0%. The two markers are both present on the overlapping BAC clones 127G6 and 134C9 suggesting that the RN gene may reside on the same clone or one of the neighbouring clones.

A shot-gun library of the BAC clone 127G6 was constructed and more than 1,000 sequence reads were collected giving about 500,000 base pair random DNA sequence from the clone. The data were analysed and sequence contigs constructed with the PHRED, PHRAP and CONSED software package (University of Washington Genome Center, <http://bozeman.mbt.washington.edu>). The sequence data were masked for repeats using the REPEATMASKER software (<http://ftp.genome.washington.edu/cgi-bin/RepeatMasker>) and BLAST searches were carried out using the NCBI web site (<http://www.ncbi.nlm.nih.gov>).

Three convincing matches to coding sequences were obtained. Two of these were against human cDNA sequences/genes, KIAA0173 described as being similar to pig tubulin-tyrosine ligase and located on HSA2q (UniGene cluster Hs.169910, <http://www.ncbi.nlm.nih.gov/UniGene/>) and CYP27A1 located on HSA2q33-ter (UniGene cluster Hs.82568). The results strongly suggested that the pig coding sequences are orthologous to these human genes as it is well established that the RN region is homologous to HSA2q33-36 (ROBIC et al., Mamm. Genome, 10, 565-568, 1999). However, none of these sequences appeared as plausible candidate genes for RN. The third coding sequence identified in BAC 127G6 showed highly significant sequence similarity to various AMP-activated protein kinase γ sequences including the yeast *SNF4* sequence. The cDNA sequence of this gene was determined by RT-PCR and RACE analysis using muscle mRNA from an *rn⁺/rn⁺* homozygote. This sequence is shown in Figure 2 and in the enclosed sequence listing under SEQ ID NO: 1.

20

Legend of Figure 2:

5' UTR: 5' untranslated region

3' UTR: 3' untranslated region

CDS: coding sequence

***: stop codon

25

`-`: identity to master sequence

`.`: alignment gap

The frame of translation was determined on the basis of homology to other members in the protein family and assuming that the first methionine codon in frame is the start codon. The deduced polypeptidic sequence is shown in the enclosed sequence listing under SEQ ID NO: 2.

Figure 3 shows an amino acid alignment constructed with the CLUSTAL W program (THOMPSON et al., Nucleic Acids Research, 22, 4673-4680, 1994) with

representative AMPK γ sequences in the nucleotide databases.

Legend of Figure 3:

Sequences used:

- 5 HumG1: Genbank U42412
 MusG1: Genbank AF036535
 HumG2: Human PRKAG2 (Genbank AJ249976)
 PigG3: pig PRKAG3 (this study)
 HumG3: human PRKAG3 (this study)
 10 Dros: *Drosophila* (Genbank AF094764)
 SNF4 (yeast): Genbank M30470
 Both the PRKAG2 and *Drosophila* sequences have longer aminoterminal regions but they do not show significant homology to the aminoterminal region of PRKAG3 and were
 15 not included.

Abbreviations:

- *: stop codon
 '-': identity to master sequence
 '.': alignment gap
 20 The four CBS domains are overlined and the position of the RN⁻ mutation is indicated by an arrow.

Table 2 below shows the amino acid (above diagonal) and nucleotide sequence (below diagonal) identities (in %) among mammalian, *Drosophila* and yeast
 25 AMPKG/SNF4 sequences.

TABLE 2

	PigG3	HumG3	HumG1	RatG1	MusG1	HumG2	Dros	SNF4
PigG3	-	97.0	64.2	64.2	63.9	62.6	53.2	34.0
HumG3	90.7	-	63.6	63.6	63.6	62.6	53.5	34.4
HumG1	64.2	64.5	-	96.7	96.3	75.6	60.9	33.5
RatG1	65.8	65.8	88.0	-	97.4	75.3	61.1	33.5
MusG1	65.3	64.8	87.2	92.8	-	74.6	61.7	33.5
HumG2	61.6	61.6	68.1	67.8	65.9	-	63.1	34.5
Dros	58.4	58.4	59.0	59.3	59.0	60.0	-	36.2
SNF4	44.0	44.2	45.4	44.6	45.3	45.7	44.8	-

Figure 4 shows a Neighbor-Joining phylogenetic tree constructed with the PAUP software (SWOFFORD, Phylogenetic analysis using parsimony (and other

methods), Sinauer Associates, Inc. Publishers, Sunderland, Massachusetts, 1998) using yeast SNF4 as outgroup; support for branch orders obtained in bootstrap analysis with 1,000 replicates are indicated, scales of tree is indicated at the bottom. The result showed that the pig gene located in the RN region is distinct from mammalian *PRKAG1* and *PRKAG2* isoforms and most likely orthologous to a human gene represented by the human EST sequence AA178898 (GenBank) derived from a muscle cDNA library. This gene is herein denoted *PRKAG3* since it is the third isoform of a mammalian AMP-activated protein kinase γ characterised so far.

The cDNA sequence of this gene was determined by RT-PCR and 5'RACE analysis using human skeletal muscle cDNA (Clontech, Palo Alto, CA) and the deduced protein sequence showed 97% identity to the porcine sequence (Figure 2; Table 2). This cDNA sequence is also shown in the enclosed sequence listing under SEQ ID NO: 3; the deduced polypeptidic sequence is shown in the enclosed sequence listing under SEQ ID NO: 4.

Using the high resolution human TNG radiation hybrid panel (<http://shgc-www.stanford.edu/RH/TNGindex.html>), we mapped the human homologs of *PRKAG3*, *CYP27A1* and *KIAA0173*, all present in the porcine BAC127G6. The three genes are also very closely linked in the human genome. *PRKAG3* was mapped at a distance of 33 cR_{50.000} from *KIAA0173* and 52 cR_{50.000} from *CYP27A1*, with lod score support of 6.8 and 4.5, respectively.

The established role of AMPK in regulating energy metabolism, including glycogen storage, and its location in the region showing maximum linkage disequilibrium made *PRKAG3* a very strong candidate gene for RN. This was further strengthened by hybridisation analysis of a human multiple tissue northern blots (CLONTECH, Palo Alto, CA) using human *PRKAG1* (IMAGE clone

0362755 corresponding to GenBank entry AA018675), human *PRKAG2* (IMAGE clone 0322735 corresponding to GenBank entry W15439) and a porcine *PRKAG3* probe. The results are shown in Figure 5.

5 Legend of Figure 5:

H: Heart, B: Brain, Pl: Placenta, L: Lung,
Li: Liver, M: Skeletal muscle, K: Kidney, Pa: Pancreas,
S: Spleen, Th: Thymus, P: Prostate, T: Testis, O: Ovary,
I: Small intestine, C: Colon (mucosal lining),
10 PBL: Peripheral Blood Leukocyte.

While the *PRKAG1* and *PRKAG2* probes showed a broad tissue distribution of expression, *PRKAG3* showed a distinct muscle-specific expression. This result is also supported by the human EST database where multiple ESTs
15 representing *PRKAG1* and *PRKAG2* have been identified in various cDNA libraries whereas a single EST (GenBank entry AA178898) representing *PRKAG3* has been obtained from a muscle cDNA library. The muscle-specific expression of *PRKAG3* and the lack of expression in liver
20 are entirely consistent with the phenotypic effect of *RN⁻*, namely that glycogen content is altered in muscle but normal in liver (ESTRADE et al., Comp. Biochem. Physiol. 104B, 321-326, 1993).

PRKAG3 sequences were determined from *rn⁺/rn⁺* and *RN⁻/RN⁻* homozygotes by RT-PCR analysis. A comparison revealed a total of seven nucleotide differences four of which were nonsynonymous substitutions was found between the sequence from *rn⁺* and *RN⁻* animals, as shown in Table 3 below. Screening of these seven SNPs with genomic DNA
30 from additional *rn⁺* and *RN⁻* pigs of different breeds revealed five different *PRKAG3* alleles, but only the R41Q missense substitution was exclusively associated with *RN⁻*. This nonconservative substitution occurs in CBS1 which is the most conserved region among isotypic forms of the
35 AMPK γ chain and arginine at this residue (number 70 in *Prkag1*) is conserved among different isoforms of

mammalian AMPK γ sequences as well as in the corresponding *Drosophila* sequence (Figure 3). A simple diagnostic DNA test for the R41Q mutation was designed based on the oligonucleotide ligation assay (OLA; LANDEGREN et al., Science, 241, 1077-1080, 1988). Screening a large number of RN^- and rn^+ animals from the Hampshire breed as well as large number of rn^+ animals from other breeds showed that the 41Q allele was present in all RN^- animals but not found in any rn^+ animals, as shown in Table 4 below. The absence of the 41Q allele from other breeds is consistent with the assumption that the RN^- allele originated in the Hampshire breed; the allele has not yet been found in purebred animals from other breeds. In conclusion, the results provide convincing evidence that *PRKAG3* is identical to the *RN* gene and that the R41Q substitution most likely is the causative mutation.

Table 3. Comparison of the *PRKAG3* sequences associated with the *rn*⁺ and *rn* alleles in different pig populations^a

Associated Allele	RN allele	nt83 nt152	Codon					Population ^b
			34	35	40	41	213	
1	RN	ACC CTC	GCC CTG	GTC CAA	TCT		H	
2	rn ⁺	T L --- ---	A L --- ---	V Q --- -G-	S ---		L, LW, WB	
3	rn ⁺	- --- -C-	- --- T--	- --- -G-	- --C		H, L, LW, M, WB	
4	rn ⁺	- -A- -C-	- --- T--	- --- -G-	- --C		D, H	
5	rn ⁺	N --- -C-	- --- T--	- A-- -G-	- --C		H, LW, WB	
15		- P	- - I	R -	-			

^anucleotide and codon numbers refer to the numbering of the sequence SEQ ID NO: 2^bH=Hampshire, L=Landrace, LW=Large White, M=Meishan, WB=Wild Boar, D=Duroc

N.D.=not determined, "-" indicates identity to the top sequence.

TABLE 4.

RN phenotype	Genotype at nucleotide 122			Total
	A/A	G/A	G/G	
RN ⁻ , Hampshire ^a	40	87	0	127
RN ⁻ , Hampshire ^{a,b}	0	13	0	13
rn ⁺ , Hampshire ^a	0	0	60	60
rn ⁺ , other breeds ^c	0	0	488	488

^arepresent both French and Swedish Hampshire populations

^bheterozygosity RN/rn^{+} deduced using pedigree information

^cbreeds: Angler Saddleback, n=31; Blond Mangalitza, n=2; Bunte Bentheimer, n=16; Duroc, n=160; Göttinger Minipig, n=4; Landrace, n=83; Large White, n=72; Meishan, n=8; Piétrain, n=75; Red Mangalitza, n=5; Rotbunte Husumer, n=15; Schwalbenbauch Mangalitza, n=7; Schwäbisch Hällische, n=2; European Wild Boar, n=5; Japanese Wild Boar, n=3.

AMPK kinase activity was measured in muscle extracts from normal rn^{+} pigs or from RN^{-} pigs in the presence or absence of AMP. Muscle tissue was collected from 4 rn^{+} (rn^{+}/rn^{+}) and 5 RN^{-} (2 RN/rn^{+} and 3 RN/RN) pigs. Muscle extract was purified up to and including the DEAE-Sepharose ion-exchange step as described by CARLING et al. [Eur. J. Biochem. 186, 129 (1989)]. AMPK activity was assayed by phosphorylation of the SAMS peptide [DAVIES et al., Eur. J. Biochem. 186, 123 (1989)]. Assays were performed in triplicates for each animal, both in the presence and absence of 200 μ M AMP. Since 0.1 μ g of total protein from the 0.2M NaCl DEAE eluates showed a linear activity both in the presence and absence of added AMP for at least 12 minutes (data not shown) we used this amount of extract and an incubation time of 10 minutes in the experiments. For each assay, controls were included that lacked added peptide and the values presented represent peptide-dependent activity.

We found that AMPK kinase activity in muscle extracts was about three-fold higher in normal rn^{+} pigs than in RN^{-} pigs both in the presence and absence of AMP (Table 4b)

Table 4b

Kinase activity ^a			
5	RN type	n	
			-AMP +AMP
	rn ⁺	4	955±134 1,519±323
	RN ⁻	5	380±122 531±292
	Significance		0.02 0.06
10	^a Phosphorylation measured as cpm incorporated P ³² /0.1µl muscle extract. Least square means ± standard errors are reported; the significance values were obtained by an F-test using a linear regression model.		
15	Without being bound to any particular mechanism, it may be hypothesised that the AMPK heterotrimer including PRKAG3 is involved in the regulation of glucose transport into skeletal muscle.		
20	It has recently been reported that AMPK activation induced by the AMP analogue AICAR or by muscle contraction leads to an increased glucose uptake in skeletal muscle (BERGERON <i>et al.</i> , <i>Am. J. Physiol.</i> , 276, E938-944, 1999; HAYASHI <i>et al.</i> , <i>Diabetes</i> , 47, 1369-1373, 1998). If this is the function of the AMPK heterotrimer		
25	including PRKAG3, R41Q may be a gain-of-function mutation causing a constitutively active holoenzyme, for instance due to the loss of an inactivating allosteric site. If so, the reduced AMPK activity in RN ⁻ animals is likely to reflect feed-back inhibition due to the high-energy		
30	status of the muscle. An increased uptake of glucose to skeletal muscle is expected to lead to an increase in muscle glycogen content as observed in RN ⁻ animals. It has been shown that overexpression of glucose transporter 4 (GLUT4) in transgenic mice leads to increased uptake of		
35	glucose and increased glycogen storage (TREADWAY <i>et al.</i> , <i>J. Biol. Chem.</i> , 269, 29956-29961, 1994). This type of gain-of-function model is consistent with the dominance of RN ⁻ as the presence of a single unregulated copy would have a large effect on AMPK enzyme activity.		

An alternative hypothesis on the functional significance of the R41Q substitution associated with the *RN* allele may also be proposed. Based on the established roles of the yeast SNF1 enzyme in utilisation of glycogen and of mammalian AMPK for inhibiting energy-consuming pathways and stimulating energy-producing pathways, activated AMPK is expected to inhibit glycogen synthesis and stimulate glycogen degradation. If this is the functional role of the isoform(s) containing the *PRKAG3* product, the R41Q substitution would be a loss-of-function mutation or a dominant-negative mutation locking the AMPK heterotrimer in an inactive state, and thus inhibiting AMP activation and glycogen degradation. In these cases the phenotypic effect should be explained by haplo-insufficiency, since *RN* appears fully dominant.

R41Q may thus be a dominant negative mutation, but only if it interferes with multiple isoforms since the major AMPK activity in muscle appears to be associated with the *PRKAG1* and 2 isoforms [CHEUNG, et al. *Biochem. J.* 346, 659 (2000)].

The distinct phenotype of the *RN* mutation indicates that *PRKAG3* plays a key role in the regulation of energy metabolism in skeletal muscle. For instance, *PRKAG3* is likely to be involved in the adaptation to physical exercise, which is associated with increased glycogen storage. It is also conceivable that loss-of-function mutations in *PRKAG3* (or other AMPK genes) may predispose individuals to noninsulin-dependent diabetes mellitus, and AMPK isoforms are potential drug targets for treatment of this disorder.

EXAMPLE 2: DETECTION OF THE R41Q SUBSTITUTION IN PIG *PRKAG3*

A part of *PRKAG3* including codon 41 was amplified in 10 µl reactions containing 100 ng genomic DNA, 0.2 mM dNTPs, 1.5 mM MgCl₂, 4.0 pmol of both forward (AMPKG3F3: 5'-GGAGCAAATGTGCAGACAAG-3') and reverse

(AMPKG3R2:5'-CCCACGAAGCTCTGCTTCTT-3') primer, 10% DMSO, 1 U of *Taq* DNA polymerase and reaction buffer (ADVANCED BIOTECH, London, UK). The cycling conditions included an initial incubation at 94°C for 5 min followed by 3 cycles at 94°C (1 min), 57°C (1 min) and 72°C (1 min), and 35 cycles of 94°C (20 sec), 55°C (30 sec) and 72°C (30 sec). Allele discrimination at nucleotide position 122 was done using the oligonucleotide ligation assay (OLA, LANDEGREN *et al.*, Science, 241, 1077-1080, 1988). The OLA method was carried out as a gel-based assay. Each 10 µl OLA reaction contained 0.5 pmol of each probe SNPRN-A (5'Hex-TGCCCAACGGCGTCCA-3'), SNPRN-G (5'ROX-GGCCAACGGCGTCCG-3') and SNPRN-Common (5'phosphate-AGCGGCACCTTTGTGAAAAAAAAA-3'), 1.5 U of thermostable AMPLIGASE and reaction buffer (EPICENTRE TECHNOLOGIES, Madison, WI) and 0.5 µl of the AMPKG3F3/AMPKG3R2 PCR product. After an initial incubation at 95°C for 5 min, the following thermocycling profile was repeated 10 times: denaturation at 94°C (30 sec), and probe annealing and ligation at 55°C (90 sec). After OLA cycling, 1 µl of product was heat denatured at 94°C (3 min), cooled on ice, and loaded onto 6% polyacrylamide denaturing gel for electrophoresis on an ABI377 DNA sequencer (PERKIN ELMER, Foster City, USA). The resulting fragment lengths and peak fluorescence were analysed using GENESCAN software (PERKIN ELMER, Foster City, USA).

The OLA-based method for the R41Q mutation was used to determine the genotype of DNA samples collected from 68 Swedish Hampshire animals phenotyped as either RN⁻ or rn⁺ based on their glycolytic potential (GP) value. Figure 6 illustrates typical OLA results from the three possible genotypes. All RN⁻ animals were scored as homozygous A/A (n=28) or heterozygous A/G (n=36) at nucleotide position 122 whereas the rn⁺ animals were homozygous G/G (n=4) at this position.

EXAMPLE 3: PREDICTING THE PRESENCE OF THE RN⁻ ALLELE USING A CLOSELY LINKED MICROSATELLITE, MS127B1

A microsatellite 127B1 (MS127B1) was cloned from BAC 127G7 containing pig PRKAG3. The BAC clone was digested with *Sau*3AI and the restriction fragments subcloned into the *Bam*HI site of pUC18. The resulting library was probed with a (CA)₁₅ oligonucleotide probe labelled with [γ -³²P]-dATP. Strongly hybridising clones were sequenced and primers for PCR amplification of microsatellite loci were designed. Ten μ l PCR reactions were performed containing 100 ng genomic DNA, 0.2 mM dNTPs, 1.5 mM MgCl₂, 4.0 pmol of both forward (MS127B1F: 5'-Fluorescein-CAAACCTCTTCTAGGCGTGT-3') and reverse (MS127B1R: 5'-GTTTCTGGAACCTCCATATGCCATGG-3') primers, and 1 U of Taq DNA polymerase and reaction buffer (ADVANCED BIOTECH, London, UK). The cycling conditions included an initial incubation at 94°C for 5 min followed by 3 cycles at 94°C (1 min), 57°C (1 min) and 72°C (1 min), and 35 cycles of 94°C (20 sec), 55°C (30 sec) and 72°C (30 sec). The PCR products (0.3 μ l) were separated using 4% polyacrylamide denaturing gel electrophoresis on an ABI377 DNA sequencer (PERKIN ELMER, Foster City, USA). The resulting fragment lengths were analysed using the GENESCAN and GENOTYPER software (PERKIN ELMER, Foster City, USA).

The method was used to determine the genotype of DNA samples collected from 87 Swedish Hampshire animals phenotyped as either RN⁻ or rn⁺ based on their glycolytic potential (GP) value. Allele 108 (bp) showed a complete association to the RN⁻ allele in this material as all RN⁻ (RN⁻/RN⁻ or RN⁻/rn⁺) animals were homozygous or heterozygous for this allele while no rn⁺ (rn⁺/rn⁺) animals carried this allele, as shown in Table 5 below.

Table 5

Animals	n	Genotype				
		94/94	94/108	94/114	100/108	108/108
RN ⁻	80	0	37	0	2	41
rn ⁺	7	3	0	4	0	0

EXAMPLE 4: DETECTING THE PRESENCE OF THE RN⁻ ALLELE USING A PCR-RFLP TEST

The RN⁻ mutation inactivates a BsrBI site
 5 GAG⁺CGG/CTC⁺GCC (BsrBI RE site is not palindromic). At that site, the RN⁻ sequence is AAGCGG instead of GAGCGG.

A 134 bp long fragment of the RN gene is amplified from porcine genomic DNA. The rn⁺ allele is identified after BsrBI digestion, by detection of two
 10 fragments of 83 and 51 bps.

The test is performed as follows:

1° Primer sequences:

Sequence of primers used to amplify the RN mutation region:

15 RNU: 5' GGGAACGATTCACCCTCAAC 3'
 RNL: 5' AGCCCCTCCTCACCCACGAA 3'

To provide an internal control of digestion, a BsrBI site has been added at the extremity of one of the two primers within a 20 bp long tail. The tail permits
 20 both creation of a BsrBI site (a shorter tail might be sufficient), and an easy discrimination of uncut fragment from other fragments. The use of tailed primers does not affect efficiency and specificity of amplification.

The sequence of the RNL modified primer
 25 including a control tail with a BsrBI site is:

RNLBsrA14: 5'

A₅C₂A₇CCGCTCAGCCCCTCCTCACCCACGAA 3'

2° PCR reaction mixture used:

30 50 ng DNA
 0.5 Unit Taq polymerase (GIBCO BRL)
 1.5 mM MgCl²

200 mM dNTP

0.2 μ M each primer

Total reaction volume: 25 μ l

5 3° PCR conditions used (on OMNIGENE HYBAID thermocycler):

1x (5min 95°C)

35x (45sec 57°C, 45sec 72°C, 45sec 95°C)

1x (45sec 57°C, 15min 72°C)

10 4° Restriction enzyme digestion performed at 37°C for 2 hours:

10 μ l PCR product

1x BsrBI BIOLABS buffer

5U BsrBI restriction enzyme (BIOLABS)

Total reaction volume: 15 μ l

15 5° Size of fragments produced after PCR using primers with control tail and digestion with BsrBI:

Uncut fragment from *RN* or *rn*⁺ allele : 154 bp

allele : 137 bp + 17 bp

20 After digestion of fragment amplified from *rn*⁺ allele : 83 bp + 54 bp + 17 bp

Size difference can be identified either after polyacrylamide, agarose/nusieve or agarose gel electrophoresis.

25

CLAIMS

1) A gamma subunit of a vertebrate AMP-activated kinase (AMPK), wherein said gamma subunit is a polypeptide having at least 70% identity with the polypeptide SEQ ID NO: 2.

2) A polypeptide of claim 1, wherein said polypeptide has at least 95% identity with the polypeptide SEQ ID NO:2.

3) A polypeptide of any of claims 1 or 2, wherein said polypeptide has the sequence SEQ ID NO: 2 or SEQ ID NO:4 or a sequence resulting from a V40I substitution in SEQ ID NO: 2.

4) A polypeptide which is a functionally altered mutant of a gamma subunit of a vertebrate AMP-activated kinase, wherein said polypeptide has at least a mutation located within the first CBS domain of said gamma subunit.

5) A polypeptide of claim 4, wherein the mutation is located within the region of the first CBS domain aligned with the region of a polypeptide of SEQ ID NO: 2 spanning from residue 30 to residue 50.

6) A polypeptide of claim 5, wherein the mutation is a R→Q substitution.

7) A polypeptide of claim 6, having a sequence resulting from a R41Q substitution in SEQ ID NO: 2.

8) A polypeptide which is a mutant of a gamma subunit of a vertebrate AMP-activated kinase, wherein said polypeptide results from a deletion of a part of a polypeptide of claim 1.

9) A nucleic acid sequence encoding a polypeptide of any of claims 1 to 8, or the complement thereof, provided that said nucleic acid sequence does not consist of the EST GENBANK AA178898.

10) A nucleic acid sequence of claim 9, having the sequence SEQ ID NO: 1 or SEQ ID NO:3, or the complement thereof.

11) A nucleic acid sequence comprising at least a portion of a nucleic acid sequence encoding a polypeptide of any of claims 1 to 8, and up to 500 kb of a 3' and/or of a 5' adjacent genomic DNA sequence, or the complement thereof.

12) A nucleic acid fragment selected among:
- a specific fragment of a nucleic acid sequence encoding a polypeptide of any of claims 1 to 8, or of a nucleic acid sequence of claim 11;
- a nucleic acid fragment which specifically hybridises under stringent conditions with a nucleic acid sequence encoding a polypeptide of any of claims 1 to 8, or of a nucleic acid sequence of claim 11;
provided that said nucleic acid fragment does not consist of the EST GENBANK AA178898.

13) A set of primers for amplifying a nucleic acid sequence of any of claims 9 to 11 or a portion thereof, comprising at least a primer consisting of a nucleic acid fragment of claim 12.

14) A recombinant vector comprising a nucleic acid sequence encoding a polypeptide of any of claims 1 to 8.

15) An host cell transformed by a nucleic acid sequence encoding a polypeptide of any of claims 1 to 8.

16) A transgenic animal transformed by a nucleic acid sequence encoding a polypeptide of any of claims 1 to 8.

17) A knockout animal, wherein the gene encoding a polypeptide of claim 1 is inactive.

18) A heterotrimeric AMPK wherein the γ subunit consists of a polypeptide of any of claims 1 to 8.

19) A method of detecting a metabolic disorder resulting from a mutation in a gene encoding a γ subunit of AMPK, wherein said process comprises:

- obtaining a nucleic acid sample from a vertebrate;

- checking the presence in said nucleic acid of a nucleic acid sequence encoding a polypeptide of any
5 of claims 1 to 8, wherein said polypeptide is functionally altered.

20) A method of claim 19 wherein the disorder is correlated with an altered glycogen accumulation in the muscular cells and results from the expression of a
10 functionally altered allele of a polypeptide of claim 1.

21) A method of any of claims 19 or 20 wherein the presence of the nucleic acid sequence encoding said mutant polypeptide is checked by contacting said nucleic acid sample with a nucleic acid probe obtained from a
15 nucleic acid of claim 12 and spanning said mutation, under conditions of specific hybridisation between said probe and the mutant sequence to be detected, and detecting the hybridisation complex.

22) A method for obtaining a pair of primers
20 allowing to detect a genetic polymorphic marker linked to a nucleic acid sequence encoding a polypeptide of claim 1, wherein said process comprises:

- screening a genomic DNA library from a vertebrate with a probe specific for a nucleic acid
25 sequence encoding a polypeptide of claim 1, in order to select clones comprising said nucleic acid sequence and flanking chromosomal sequences;

- identifying a polymorphic locus in said flanking chromosomal sequences, and sequencing a DNA
30 segment comprising said polymorphic locus ;

- designing primer pairs flanking said polymorphic locus.

23) A method of claim 22 wherein the selected clones comprise at least a portion of a nucleic acid
35 sequence encoding a polypeptide of claim 1, and up to 500 kb of a 3' and/or of a 5' adjacent sequence.

24) A method of any of claims 19 to 23 wherein the vertebrate is a mammal.

25) A method of claim 24 wherein said mammal is a pig.

5 26) A pair of primers obtainable by the process of any of claims 21 to 25.

27) A process for detecting a dysfunction of carbohydrate metabolism resulting from the expression of a functionally altered allele of a polypeptide of claim 1
10 in a vertebrate, wherein said process comprises:

- obtaining a sample of genomic DNA from said vertebrate;

- contacting said DNA with a pair of primers of claim 26 under conditions allowing PCR amplification;

15 - analysing the PCR product to detect if an allele of a polymorphic marker linked to a nucleic acid sequence encoding a functionally altered allele of a polypeptide of claim 1 is present.

28) A process of claim 27, wherein said
20 functionally altered polypeptide results from a R41Q substitution.

29) A process of any of claims 27 or 28, wherein said vertebrate is a mammal.

30) A process of claim 29 wherein said mammal
25 is a pig.

31) A process of claim 30 wherein the pair of primers is selected among:

- a pair of primers consisting of SEQ ID NO: 5 and SEQ ID NO: 6;

30 - a pair of primers consisting of SEQ ID NO: 7 and SEQ ID NO: 8;

- a pair of primers consisting of SEQ ID NO: 9 and SEQ ID NO: 10;

35 - a pair of primers consisting of SEQ ID NO: 11 and SEQ ID NO: 12;

- a pair of primers consisting of
SEQ ID NO: 13 and SEQ ID NO: 14;
- a pair of primers consisting of
SEQ ID NO: 15 and SEQ ID NO: 16;
- 5 - a pair of primers consisting of
SEQ ID NO: 17 and SEQ ID NO: 18;
- a pair of primers consisting of
SEQ ID NO: 19 and SEQ ID NO: 20;
- 10 - a pair of primers consisting of
SEQ ID NO: 21 and SEQ ID NO: 22;
- a pair of primers consisting of
SEQ ID NO: 23 and SEQ ID NO: 24;
- a pair of primers consisting of
SEQ ID NO: 25 and SEQ ID NO: 26.
- 15 32) Use of a transformed cell of claim 15 to
screen compounds able to modulate AMPK activity.
- 33) Use of a transgenic animal of claim 16 to
screen compounds able to modulate AMPK activity.
- 20 34) Use of a knockout animal of claim 17 to
screen compounds able to modulate energy metabolism in
the absence of a functional polypeptide of claim 1.
- 35) Use of an heterotrimeric AMPK of claim 18
to screen compounds able to modulate AMPK activity.

THIS PAGE BLANK (USPTO)

ABSTRACT

The invention concerns variants of the gamma chain of vertebrate AMP-activated kinase (AMPK), as well as nucleic acid sequences encoding said variants and use thereof for the diagnosis or treatment of dysfunction of energy metabolisms.

THIS PAGE BLANK (USPTO)

1/13


Figure 1. Linkage disequilibrium in the *RN* region

Figure 2. Alignment of pig and human *PRKAG3* cDNA sequences and deduced amino acid sequences

	5' UTR	10	20	30	40	50	60	70	80
Pig	TTCCTAGAGCAAGGAGAGAGCCGTT	100	110	120	130	140	150	160	
Hum	-----A-A-C-----A-C-----A-C-----G-----G-----T-----G-----A-A-G-A-								
Pig	GAACAAGGCCTCTAGATGGACAAGGCAGGAGGATGTAGAGGAAGGGGGGCTCCGGGCCCCGAGGGAAGGTCCCCAGTCCA	170	180	190	200	210	220	230	240
Hum	-GC---A---TG-----A---TCG---G-----A---A---A---T-A-G-----G-----								
Pig	GGCCAGTTGCTGAGTCCACCGGGCAGGAGGCCACATTCCCCAAGGCCACACCCCTTGGCCCAAGCCGCTCCCTTGCCCGAG	250	260	270	280	290	300	310	320
Hum	-----AC-----T-----A-----T-----T-A-----...T-----G-----								
Pig	GTGGACAACCCCCAACAGAGCGGGACATCCTCCCCTCTGACTGTGCAGCCTCAGCCTCCGACTCCAACACAGACCATCT	330	340	350	360	370	380	390	400
Hum	---G---CT---A---G-T---TG-----A-----TG-A-G-----G-----TG---G---								
Pig	GGATCTGGGCATAGAGTCTCAGCCTCGGCGGCGTCCGGGGGATGAGCTTG...GGCTGGTGAAGAGAAGCCAGCCCCGT	410	420	430	440	450	460	470	5' UTR
Hum	---G---C---CG-----C---A-A---C-G---A-TG-----A-AAG-C---C-----G---T---T---								
Pig	GCCCATCCCCAGAGGTGCTGTTACCCAGGCTGGGCTGGGATGATGAGCTGCAGAAGCCGGGGGCCAGGTCTAC								
Hum	---TG-----GC---CC-CA---T---A-----C---A---G---A---C---C-----A-----								
	CDS								
Pig	ATG CAC TTC ATG CAG GAG CAC ACC TGC TAC GAT GCC ATG GCG ACC AGC TCC AAA CTG GTC	10							20
Hum	Met His Phe Met Gln Glu His Thr Cys Tyr Asp Ala Met Ala Thr Ser Ser Lys Leu Val								
	---G---Arg---Phe---Met---Gln---Glu---His---Thr---Cys---Tyr---Asp---Ala---Met---Ala---Thr---Ser---Ser---Lys---Leu---Val---								
Pig	ATC TTC GAC ACC ATG CTG GAG ATC AAG AAG GCC TTC TTT GCC CTG GTG GCC AAC GGC GTC	30							40
Hum	Ile Phe Asp Thr Met Leu Glu Ile Lys Lys Ala Phe Phe Ala Leu Val Ala Asn Gly Val								
	---T---G---Arg---Phe---Asp---Thr---Met---Leu---Glu---Ile---Lys---Lys---Ala---Phe---Phe---Ala---Leu---Val---Ala---Asn---Gly---Val---								
Pig	CGA GCG GCA CCT TTG TGG GAC AGC AAG AAG CAG AGC TTC GTG GGG ATG CTG ACC ATC ACA	50							60
Hum	Arg Ala Ala Pro Leu Trp Asp Ser Lys Lys Gln Ser Phe Val Gly Met Leu Thr Ile Thr								
	---G---A---C---C-A---Asp---Ser---Lys---Lys---Gln---Ser---Phe---Val---Gly---Met---Leu---Thr---Ile---Thr---								
Pig	GAC TTC ATC TTG GTG CTG CAC CGC TAT TAC AGG TCC CCC CTG GTC CAG ATC TAC GAG ATT	70							80
Hum	Asp Phe Ile Leu Val Leu His Arg Tyr Tyr Arg Ser Pro Leu Val Gln Ile Tyr Glu Ile								
	---C---T---C---T---Arg---Tyr---Tyr---Arg---Ser---Pro---Leu---Val---Gln---Ile---Tyr---Glu---Ile---								
Pig	GAA GAA CAT AAG ATT GAG ACC TGG AGG GAG ATC TAC CTT CAA GGC TGC TTC AAG CCT CTG	90							100
Hum	Glu Glu His Lys Ile Glu Thr Trp Arg Glu Ile Tyr Leu Gln Gly Cys Phe Lys Pro Leu								
	---C---Gln---His---Lys---Ile---Glu---Thr---Trp---Arg---Glu---Ile---Tyr---Leu---Gln---Gly---Cys---Phe---Lys---Pro---Leu---								
Pig	GTC TCC ATC TCT CCC AAT GAC AGC CTG TTC GAA GCT GTC TAC GCC CTC ATC AAG AAC CGG	110							120
Hum	Val Ser Ile Ser Pro Asn Asp Ser Leu Phe Glu Ala Val Tyr Ala Leu Ile Lys Asn Arg								
	---T---T---T---T---Asn---Asp---Ser---Leu---Phe---Glu---Ala---Val---Tyr---Ala---Leu---Ile---Lys---Asn---Arg---								
Pig	ATC CAC CGC CTG CCG GTC CTG GAC CCT GTC TCC GGG GCT GTG CTC CAC ATC CTC ACA CAT	130							140
Hum	Ile His Arg Leu Pro Val Leu Asp Pro Val Ser Gly Ala Val Leu His Ile Leu Thr His								
	---T---								
Pig	AAG CGG CTT CTC AAG TTC CTG CAC ATC TTT GGC ACC CTG CTG CCC CGG CCC TCC TTC CTC	150							160
Hum	Lys Arg Leu Leu Lys Phe Leu His Ile Phe Gly Thr Leu Leu Pro Arg Pro Ser Phe Leu								
	---A---C---G---Lys---Arg---Leu---Leu---Lys---Phe---Leu---His---Ile---Phe---Gly---Thr---Leu---Leu---Pro---Arg---Pro---Ser---Phe---Leu---								

170

18-05-2000

EP00401388.4

DRAW

4/13

	650	660	670	680	690	700	710	720
Pig							
Hum	ACCCCTGAGAATGAGCAATTGAGAAAACAAAACAAAAGGAACAATCCATGAACTTAGATTTTATTGGTTTCACTCAAAT							
	730	740						
Pig							
Hum	GCTGCAGTCATTGACCTG							

Printed:25-01-2001


A

PigG3 MSFLEQGESRWPSPRAVTTSSERSHGQGNKASRWTRQEDVEEGPPGPPQSRPVAESTQCATPKATPLAQAPLAEDVNDPPTERDILPSCDRAAS 100
 HumG3 -----P-----S-----IR-KRRA--L-----KS-----E-QG--R--T-----L-----T-----D--G-GT--GW-C-----T-- 100
 PigG3 ASDSNTDHLGIEFSAASGDEL.GLVEEKPAPCSPSEVLLPRLGWDELQKPGAQVYMHFMQEHCTYDAMATSSKLVIEDTMLEIKKAFFALVANGV 200
 HumG3 --AG-S--DVE-AT--P-TE-WEC--E-L-R-L-L--QAPF-K-----R-----I--R-----
 HumG1 METVIS--DSSPAVENEHPQ--TPESNNS--TS--KS-R--LIP-----V--S-QV-----T--
 HumG2 AALGPAEAGM-EKLEFE-EAVEDSESG--R--RS-K--IVP-----V--T-QV-----T--
 Dros RDSRGLPVADPPFLEKVNLS--EEDDS--IFVK--FRF-K--LIP-A--V--Q-LV--Y--Y--
 Snf4 MK--TQDSQEKVSIQQLAVES..IRK-LNSK-S--VLPV-YR-IVL--S-LV--SLNV-LQ-SI 300
 PigG3 KAAPLMSKKQSFVGMLTITDFILVHLRYRSPLVQIYEIEEHKIETWREYVLCGFKPL..VSISPNDSEAVYALIKNRIHRLPVDPVSCA...V 300
 HumG3 -----NI--K-A--L-----V--DS--C--A--D-SS-R-K--I--E-N--T--
 HumG1 -----NI--K-M--L-----L--ET--N--DA--D--S--K--I--I-N--A--
 Dros E-T-SL-----Q-----Q-----
 Snf4 VS-----TSR-A-L-T--N-IQY-FSN-D.KFELVDKLQDLGLKD-ERALGVQDQ-DTA--H-SRP--CLKMLES-SG-I-LI-QDEETHREI-
 PigG3 LHILTHKRLKFLHIFGTLPRPSFLYRTIQDLGIGTFRDLAWLETAPILTALDIFVDRRVSAIPVNVETGQVGLYSRFDVIHLAAQOQTYNHLDNMVNG 400
 HumG3 -----S-----
 HumG1 -Y--I--KL-I-EF-K-E-MKSLEE-Q--YANI-M-RT-T-VYV-G-QH-----D-K-R-DI-K--N--EK--N--S--T--
 HumG2 -Y--I--QL-MSDM-K-A-MKQNLDE--YINI-FIHPT--IK-N-E-I--D-S-K-DI-K--N--EK--N--IT-T--
 Dros -Y--I-R-FLYNE-K-AYMQKSLRE-K--YNNIETAD--TS-I--KK-E-----L-DSD-RL-DI-AK--N--EK--D--VSLR
 Snf4 VSV--QY-I--VALNCRE...TH--KIP-G-N-I-QDNMKSCQM-T-VIDVIQMLTQG--SV-IID-N-YLINV-EAY--LG-IKGGI--D-SLS--
 PigG3 EALRQRTLCLEGLVSCQPHETLGEVIDRIVREQVHRLVLVDETHLGVVSLSDILQALVLSPAGIDALGA* 472
 HumG3 -----S-----A-----
 HumG1 K-QH-SHYF--K-YL--ETI-N-L-EAE--V--NDVVK-I-----TGGEKKP*
 HumG2 Q-QH-SQYF--VK-NKL-I-ETIV--AE--V-N-ADSIIV-II-----I-T--AKQKETETE*
 Dros K-NEH-NEWF--QK-NLD-S-YTIME--AE--V--NRKVI-II--LY--R-S-EGV
 Snf4 --MR-SDDF--YT-TKNDK-STIM-N-RKAR--FFV--DVGR-V--LT-----KYIL-GSN*

Figure 3

6/13

Figure 4. Neighbor-joining tree constructed for mammalian, *Drosophila* and yeast AMPKG/SNF4 amino acid sequences.



7/13

Figure 5. Northern blot analysis of human mRNA using human *PRKAG1*, human *PRKAG2* and porcine *PRKAG3* probes





Figure 6. Detection of the missense mutation at nucleotide position 122 in *PRKAG3* associated with *RN-* allele in pigs using the OLA method.



9/13

Pig PRKAG3 Splice variant 1

ATG GAG CTT GCC GAG CTA GAG CAG GCA CTG CGC AGG GTC CCG GGG TCC CGG GGG
GGC TGG GAG CTG GAG CAA CTG AGG CCA GAG GGC AGA GGG CCC ACC ACT GCG GAT
ACT CCC TCC TGG AGC AGC CTC GGG GGA CCT AAG CAT CAA GAG ATG AGC TTC CTA
GAG CAA GGA GAG AGC CGT TCA TGG CCA TCC CGA GCT GTA ACC ACC AGC TCA GAA
AGA AGC CAT GGG GAC CAG GGG AAC AAG GCC TCT AGA TGG ACA AGG CAG GAG GAT
GTA GAG GAA GGG GGG CCT CCG GGC CCG AGG GAA GGT CCC CAG TCC AGG CCA GTT
GCT GAG TCC ACC GGG CAG GAG GCC ACA TTC CCC AAG GCC ACA CCC TTG GCC CAA
GCC GCT CCC TTG GCC GAG GTG GAC AAC CCC CCA ACA GAG CGG GAC ATC CTC CCC
TCT GAC TGT GCA GCC TCA GCC TCC GAC TCC AAC ACA GAC CAT CTG GAT CTG GGC
ATA GAG TTC TCA GCC TCG GCG GCG TCG GGG GAT GAG CTT GGG CTG GTG GAA GAG
AAG CCA GCC CCG TGC CCA TCC CCA GAG GTG CTG TTA CCC AGG CTG GGC TGG GAT
GAT GAG CTG CAG AAG CCG GGG GCC CAG GTC TAC ATG CAC TTC ATG CAG GAG CAC
ACC TGC TAC GAT GCC ATG GCG ACC AGC TCC AAA CTG GTC ATC TTC GAC ACC ATG
CTG GAG ATC AAG AAG GCC TTC TTT GCC CTG GTG GCC AAC GGC GTC CGA GCG GCA
CCT TTG TGG GAC AGC AAG AAG CAG AGC TTC GTG GGG ATG CTG ACC ATC ACA GAC
TTC ATC TTG GTG CTG CAC CGC TAT TAC AGG TCC CCC CTG GTC CAG ATC TAC GAG
ATT GAA GAA CAT AAG ATT GAG ACC TGG AGG GAG ATC TAC CTT CAA GGC TGC TTC
AAG CCT CTG GTC TCC ATC TCT CCC AAT GAC AGC CTG TTC GAA GCT GTC TAC GCC
CTC ATC AAG AAC CGG ATC CAC CGC CTG CCG GTC CTG GAC CCT GTC TCC GGG GCT
GTG CTC CAC ATC CTC ACA CAT AAG CGG CTT CTC AAG TTC CTG CAC ATC TTT GGC
ACC CTG CTG CCC CGG CCC TCC TTC CTC TAC CGC ACC ATC CAA GAT TTG GGC ATC
GGC ACA TTC CGA GAC TTG GCC GTG GTG CTG GAA ACG GCG CCC ATC CTG ACC GCA
CTG GAC ATC TTC GTG GAC CGG CGT GTG TCT GCG CTG CCT GTG GTC AAC GAA ACT

GGA CAG GTA GTG GGC CTC TAC TCT CGC TTT GAT GTG ATC CAC CTG GCT GCC CAA
CAA ACA TAC AAC CAC CTG GAC ATG AAT GTG GGA GAA GCC CTG AGG CAG CGG ACA
CTG TGT CTG GAA GGC GTC CTT TCC TGC CAG CCC CAC GAG ACC TTG GGG GAA GTC
ATT GAC CGG ATT GTC CGG GAA CAG GTG CAC CGC CTG GTG CTC GTG GAT GAG ACC

Figure 7a

10/13

CAG CAC CTT CTG GGC GTG GTG TCC CTC TCT GAC ATC CTT CAG GCT CTG GTG CTC
AGC CCT GCT GGA ATT GAT GCC CTC GGG GCC TGA GAA CCT TGG AAC CTT TGC TCT
CAG GCC ACC TGG CAC ACC TGG AAG CCA GTG AAG GGA GCC GTG GAC TCA GCT CTC
ACT TCC CCT CAG CCC CAC TTG CTG GTC TGG CTC TTG TTC AGG TAG GCT CCG CCC
GGG GCC CCT GGC CTC AGC ATC AGC CCC TCA GTC TCC CTG GGC ACC CAG ATC TCA
GAC TGG GGC ACC CTG AAG ATG GGA GTG GCC CAG CTT ATA GCT GAG CAG CCT TGT
GAA ATC TAC CAG CAT CAA GAC TCA CTG TGG GAC CAC TGC TTT GTC CCA TTC TCA
GCT GAA ATG ATG GAG GGC CTC ATA AGA GGG GTG GAC AGG GCC TGG AGT AGA GGC
CAG ATC AGT GAC GTG CCT TCA GGA CCT CCG GGG AGT TAG AGC TGC CCT CTC TCA
GTT CAG TTC CCC CCT GCT GAG AAT GTC CCT GGA AGG AAG CCA GTT AAT AAA CCT
TGG TTG GAT GGA ATT TGG AGA GTC

Figure 7a (continued)

11/13

Pig PRKAG3 splice variant 2

MELAELEQAL RRVPGSRGGW ELEQLRPEGR GPTTADTPSW SSLGGPKHQE MSFLEQGESR
SWPSRAVTTS SERSHGDQGN KASRWTRQED VEEGGPPGPR EGPOSRPVAE STGQEATFPK
ATPLAQAAPL AEVDNPPTER DILPSDCAAS ASDSNTDHL D LGIEFSASAA SGDELGLVEE
KPAPCPSPEV LLPRLGWDDE LQKPGAQVYM HFMQEHTCYD AMATSSKLVI FDTMLEIKKA
FFALVANGVR AAPLWDSKKQ SFVGMLTITD FILVLHRYR SPLVQIYEIE EHKIETWREI
YLQGC FKPLV SISPND SLFE AVYALIKNRI HRLPVLD PVS GAVLHILTHK RLLKFLHIFG
TLLPRPSFLY RTIQDLGIGT FRDLAVVLET APILTALDIF VDRRV SALPV VNETGQVVGL
YSREFDVIHLA AQQTYNH LDM NVGEALRQRT LCLEGV LSCQ PHETLGEVID RIVREQVHRL
VLVDETQHLL GVVSLSDILQ ALVLSPAGID ALGA*

Figure 7b

12/13

Pig PRKAG3 Splice variant 2

CT CAG AGG GGG ACA TCT GGA CAC ACA CTG GCC ATC CTC CCG GGA CCA CCC ACG AAC TCC
GCC TCC CCA GCC TCC CAG CTG GCT GCA ACT AGC CCT TTC TAA CCC CAG TGC CAC CCA CGA
CCG GAG TTT GTA CAA GGA AGA AAG TTA AGC TCA ACT TGC TTG CAT TTT CCC TCC TTT GGC
GGC TGG CAA ATG AGA GAG GCC CTC ACG GTG GGA ACA CAG CGG GGG CTC TGA GAG CAT ACC
CTC CTC CCA CCC CAG TTC CAA GCT GCT TCC CCC ACA GAG GAT CCT TCT CAC CTG TCC TCA
GAG ACC CAG GAG ACA GCC CGG GAC CAG GCA TCA AGA TTC CAG ACT CCC TCC TGG AGC AGC
CTC GGG GGA CCT AAG CAT CAA GAG ATG AGC TTC CTA GAG CAA GGA GAG AGC CGT TCA TGG
CCA TCC CGA GCT GTA ACC ACC AGC TCA GAA AGA AGC CAT GGG GAC CAG GGG AAC AAG GCC
TCT AGA TGG ACA AGG CAG GAG GAT GTA GAG GAA GGG GGG CCT CCG GGC CCG AGG GAA GGT
CCC CAG TCC AGG CCA GTT GCT GAG TCC ACC GGG CAG GAG GCC ACA TTC CCC AAG GCC ACA
CCC TTG GCC CAA GCC GCT CCC TTG GCC GAG GTG GAC AAC CCC CCA CAG CGG GAC ATC
CTC CCC TCT GAC TGT GCA GCC TCA GCC TCC GAC TCC AAC ACA GAC CAT CTG GAT CTG GGC
ATA GAG TTC TCA GCC TCG GCG GCG TCG GGG GAT GAG CTT GGG CTG GTG GAA GAG AAG CCA
GCC CCG TGC CCA TCC CCA GAG GTG CTG TTA CCC AGG CTG GGC TGG GAT GAT GAG CTG CAG
AAG CCG GGG GCC CAG GTC TAC ATG CAC TTC ATG CAG GAG CAC ACC TGC TAC GAT GCC ATG
GCG ACC AGC TCC AAA CTG GTC ATC TTC GAC ACC ATG CTG GAG ATC AAG AAG GCC TTC TTT
GCC CTG GTG GCC AAC GGC GTC CGA GCG GCA CCT TTG TGG GAC AGC AAG AAG CAG AGC TTC
GTG GGG ATG CTG ACC ATC ACA GAC TTC ATC TTG GTG CTG CAC CGC TAT TAC AGG TCC CCC
CTG GTC CAG ATC TAC GAG ATT GAA GAA CAT AAG ATT GAG ACC TGG AGG GAG ATC TAC CTT
CAA GGC TGC TTC AAG CCT CTG GTC TCC ATC TCT CCC AAT GAC AGC CTG TTC GAA GCT GTC
TAC GCC CTC ATC AAG AAC CGG ATC CAC CGC CTG CCG GTC CTG GAC CCT GTC TCC GGG GCT
GTG CTC CAC ATC CTC ACA CAT AAG CGG CTT CTC AAG TTC CTG CAC ATC TTT GGC ACC CTG
CTG CCC CGG CCC TCC TTC CTC TAC CGC ACC ATC CAA GAT TTG GGC ATC GGC ACA TTC CGA
GAC TTG GCC GTG GTG CTG GAA ACG GCG CCC ATC CTG ACC GCA CTG GAC ATC TTC GTG GAC
CGG CGT GTG TCT GCG CTG CCT GTG GTC AAC GAA ACT GGA CAG GTA GTG GGC CTC TAC TCT
CGC TTT GAT GTG ATC CAC CTG GCT GCC CAA CAA ACA TAC AAC CAC CTG GAC ATG AAT GTG
GGA GAA GCC CTG AGG CAG CGG ACA CTG TGT CTG GAA GGC GTC CTT TCC TGC CAG CCC CAC
GAG ACC TTG GGG GAA GTC ATT GAC CGG ATT GTC CGG GAA CAG GTG CAC CGC CTG GTG CTC
GTG GAT GAG ACC CAG CAC CTT CTG GGC GTG GTG TCC CTC TCT GAC ATC CTT CAG GCT CTG
GTG CTC AGC CCT GCT GGA ATT GAT GCC CTC GGG GCC TGA GAA CCT TGG AAC CTT TGC TCT
CAG GCC ACC TGG CAC ACC TGG AAG CCA GTG AAG GGA GCC GTG GAC TCA GCT CTC ACT TCC
CCT CAG CCC CAC TTG CTG GTC TGG CTC TTG TTC AGG TAG GCT CCG CCC GGG GCC CCT GGC
CTC AGC ATC AGC CCC TCA GTC TCC CTG GGC ACC CAG ATC TCA GAC TGG GGC ACC CTG AAG
ATG GGA GTG GCC CAG CTT ATA GCT GAG CAG CCT TGT GAA ATC TAC CAG CAT CAA GAC TCA
CTG TGG GAC CAC TGC TTT GTC CCA TTC TCA GCT GAA ATG ATG GAG GGC CTC ATA AGA GGG
GTG GAC AGG GCC TGG AGT AGA GGC CAG ATC AGT GAC GTG CCT TCA GGA CCT CCG GGG AGT
TAG AGC TGC CCT CTC TCA GTT CAG TTC CCC CCT GCT GAG AAT GTC CCT GGA AGG AAG CCA
GTT AAT AAA CCT TGG TTG GAT GGA ATT TGG AGA GTC

Figure 8a

13/13

Fig PRKAG3 Splice variant 2

MSFLEQGESR SWPSRAVTTS SERSHGDQGN KASRWTRQED VEEGGPPGPR EGPQSRPVAE
STGQEATFPK ATPLAQAPL AEVDNPPTER DILPSDCAAS ASDSNTDHLD LGIEFSASAA
SGDELGLVEE KPAPCPSPEV LLPRLGWDDE LQKPGAQVYM HFMQEHTCYD AMATSSKLVI
FDTMLEIKKA FFALVANGVR AAPLWDSKKQ SFVGMLTITD FILVLHRYR SPLVQIYEIE
EHKIETWREI YLQGCfkPLV SISPNDLFE AVYALIKNRI HRLPVLDVPS GAVLHILTHK
RLLKFLHIFG TLLPRPSFLY RTIQDLGIGT FRDLAVVLET APILTALDIF VDRRVSalpV
VNETGQVVGL YSRFDVIHLA AQQTYNHLDN NVGEALRQRT LCLEGLVSCQ PHETLGEVID
RIVREQVHRL VLVDETQHLL GVVSLSDILQ ALVLSPAGID ALGA*

Figure 8b

THIS PAGE BLANK (USPTO)

2013/04/15 14:00

SEQUENCE LISTING

<110> INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE
ANDERSSON, LEIF
LOOFT, CHRISTIAN
KALM, ERNST

<120> VARIANTS OF THE GAMMA CHAIN OF AMPK, DNA SEQUENCES ENCODING
THE SAME, AND USES THEREOF

<130> MJPcb539/99bEP

<140>

<141>

<160> 26

<170> PatentIn Ver. 2.1

<210> 1

<211> 1867

<212> DNA

<213> Sus scrofa

<220>

<221> CDS

<222> (472) .. (1389)

<400> 1

```

ttcctagagc aaggagagag ccgttcatgg ccatcccgag ctgtaaccac cagctcagaa 60
agaagccatg gggaccaggg gaacaaggcc tctagatgga caaggcagga ggatgtagag 120
gaagggggggc ctccggggccc gaggggaaggt ccccgagtcca ggccagttgc tgagtccacc 180
gggcaggagg ccacattccc caaggccaca cccttggccc aagccgctcc cttggccgag 240
gtggacaacc cccaacaga gcgggacatc ctcccctctg actgtgcagc ctcagcctcc 300
gactccaaca cagaccatct ggatctgggc atagagttct cagcctcggc ggcgtcgggg 360
gatgagcttg ggctggtgga agagaagcca gccccgtgcc catccccaga ggtgctgtta 420
cccaggctgg gctgggatga tgagctgcag aagccggggg cccaggtcta c atg cac 477
                                         Met His
                                         1

```

```

ttc atg cag gag cac acc tgc tac gat gcc atg gcg acc agc tcc aaa 525
Phe Met Gln Glu His Thr Cys Tyr Asp Ala Met Ala Thr Ser Ser Lys
      5              10              15

```

```

ctg gtc atc ttc gac acc atg ctg gag atc aag aag gcc ttc ttt gcc 573
Leu Val Ile Phe Asp Thr Met Leu Glu Ile Lys Lys Ala Phe Phe Ala
      20              25              30

```

```

ctg gtg gcc aac ggc gtc cga gcg gca cct ttg tgg gac agc aag aag 621
Leu Val Ala Asn Gly Val Arg Ala Ala Pro Leu Trp Asp Ser Lys Lys
      35              40              45              50

```

cag agc ttc gtg ggg atg ctg acc atc aca gac ttc atc ttg gtg ctg 669
 Gln Ser Phe Val Gly Met Leu Thr Ile Thr Asp Phe Ile Leu Val Leu
 55 60 65

cac cgc tat tac agg tcc ccc ctg gtc cag atc tac gag att gaa gaa 717
 His Arg Tyr Tyr Arg Ser Pro Leu Val Gln Ile Tyr Glu Ile Glu Glu
 70 75 80

cat aag att gag acc tgg agg gag atc tac ctt caa ggc tgc ttc aag 765
 His Lys Ile Glu Thr Trp Arg Glu Ile Tyr Leu Gln Gly Cys Phe Lys
 85 90 95

cct ctg gtc tcc atc tct ccc aat gac agc ctg ttc gaa gct gtc tac 813
 Pro Leu Val Ser Ile Ser Pro Asn Asp Ser Leu Phe Glu Ala Val Tyr
 100 105 110

gcc ctc atc aag aac cgg atc cac cgc ctg ccg gtc ctg gac cct gtc 861
 Ala Leu Ile Lys Asn Arg Ile His Arg Leu Pro Val Leu Asp Pro Val
 115 120 125 130

tcc ggg gct gtg ctc cac atc ctc aca cat aag cgg ctt ctc aag ttc 909
 Ser Gly Ala Val Leu His Ile Leu Thr His Lys Arg Leu Leu Lys Phe
 135 140 145

ctg cac atc ttt ggc acc ctg ctg ccc cgg ccc tcc ttc ctc tac cgc 957
 Leu His Ile Phe Gly Thr Leu Leu Pro Arg Pro Ser Phe Leu Tyr Arg
 150 155 160

acc atc caa gat ttg ggc atc ggc aca ttc cga gac ttg gcc gtg gtg 1005
 Thr Ile Gln Asp Leu Gly Ile Gly Thr Phe Arg Asp Leu Ala Val Val
 165 170 175

ctg gaa acg gcg ccc atc ctg acc gca ctg gac atc ttc gtg gac cgg 1053
 Leu Glu Thr Ala Pro Ile Leu Thr Ala Leu Asp Ile Phe Val Asp Arg
 180 185 190

cgt gtg tct gcg ctg cct gtg gtc aac gaa act gga cag gta gtg ggc 1101
 Arg Val Ser Ala Leu Pro Val Val Asn Glu Thr Gly Gln Val Val Gly
 195 200 205 210

ctc tac tct cgc ttt gat gtg atc cac ctg gct gcc caa caa aca tac 1149
 Leu Tyr Ser Arg Phe Asp Val Ile His Leu Ala Ala Gln Gln Thr Tyr
 215 220 225

aac cac ctg gac atg aat gtg gga gaa gcc ctg agg cag cgg aca ctg 1197
 Asn His Leu Asp Met Asn Val Gly Glu Ala Leu Arg Gln Arg Thr Leu
 230 235 240

tgt ctg gaa ggc gtc ctt tcc tgc cag ccc cac gag acc ttg ggg gaa 1245
 Cys Leu Glu Gly Val Leu Ser Cys Gln Pro His Glu Thr Leu Gly Glu
 245 250 255

gtc att gac cgg att gtc cgg gaa cag gtg cac cgc ctg gtg ctc gtg 1293
 Val Ile Asp Arg Ile Val Arg Glu Gln Val His Arg Leu Val Leu Val
 260 265 270

gat gag acc cag cac ctt ctg ggc gtg gtg tcc ctc tct gac atc ctt 1341
 Asp Glu Thr Gln His Leu Leu Gly Val Val Ser Leu Ser Asp Ile Leu
 275 280 285 290

cag gct ctg gtg ctc agc cct gct gga att gat gcc ctc ggg gcc tga 1389
Gln Ala Leu Val Leu Ser Pro Ala Gly Ile Asp Ala Leu Gly Ala
295 300 305

gaaccttgga acctttgctc tcaggccacc tggcacacct ggaagccagt gaagggagcc 1449
gtggactcag ctctcacttc ccctcagccc cacttgctgg tctggctctt gttcaggtag 1509
gtcccgcccc gggccccctgg cctcagcatc agcccctcag tctccctggg caccagatc 1569
tcagactggg gcaccctgaa gatgggagtg gccagctta tagctgagca gccttgtgaa 1629
atctaccagc atcaagactc actgtgggac cactgctttg tcccattctc agctgaaatg 1689
atggagggcc tcataagagg ggtggacagg gcctggagta gaggccagat cagtgcgtg 1749
ccttcaggac ctccggggag ttagagctgc cctctctcag ttcagttccc cctgctgag 1809
aatgtccctg gaaggaagcc agttaataaa ccttggttgg atggaatttc cacactcg 1867

<210> 2
<211> 305
<212> PRT
<213> Sus scrofa

<400> 2

Met His Phe Met Gln Glu His Thr Cys Tyr Asp Ala Met Ala Thr Ser
1 5 10 15
Ser Lys Leu Val Ile Phe Asp Thr Met Leu Glu Ile Lys Lys Ala Phe
20 25 30
Phe Ala Leu Val Ala Asn Gly Val Arg Ala Ala Pro Leu Trp Asp Ser
35 40 45
Lys Lys Gln Ser Phe Val Gly Met Leu Thr Ile Thr Asp Phe Ile Leu
50 55 60
Val Leu His Arg Tyr Tyr Arg Ser Pro Leu Val Gln Ile Tyr Glu Ile
65 70 75 80
Glu Glu His Lys Ile Glu Thr Trp Arg Glu Ile Tyr Leu Gln Gly Cys
85 90 95
Phe Lys Pro Leu Val Ser Ile Ser Pro Asn Asp Ser Leu Phe Glu Ala
100 105 110
Val Tyr Ala Leu Ile Lys Asn Arg Ile His Arg Leu Pro Val Leu Asp
115 120 125
Pro Val Ser Gly Ala Val Leu His Ile Leu Thr His Lys Arg Leu Leu
130 135 140
Lys Phe Leu His Ile Phe Gly Thr Leu Leu Pro Arg Pro Ser Phe Leu
145 150 155 160
Tyr Arg Thr Ile Gln Asp Leu Gly Ile Gly Thr Phe Arg Asp Leu Ala
165 170 175

Val Val Leu Glu Thr Ala Pro Ile Leu Thr Ala Leu Asp Ile Phe Val
 180 185 190

Asp Arg Arg Val Ser Ala Leu Pro Val Val Asn Glu Thr Gly Gln Val
 195 200 205

Val Gly Leu Tyr Ser Arg Phe Asp Val Ile His Leu Ala Ala Gln Gln
 210 215 220

Thr Tyr Asn His Leu Asp Met Asn Val Gly Glu Ala Leu Arg Gln Arg
 225 230 235 240

Thr Leu Cys Leu Glu Gly Val Leu Ser Cys Gln Pro His Glu Thr Leu
 245 250 255

Gly Glu Val Ile Asp Arg Ile Val Arg Glu Gln Val His Arg Leu Val
 260 265 270

Leu Val Asp Glu Thr Gln His Leu Leu Gly Val Val Ser Leu Ser Asp
 275 280 285

Ile Leu Gln Ala Leu Val Leu Ser Pro Ala Gly Ile Asp Ala Leu Gly
 290 295 300

Ala
 305

<210> 3
 <211> 2109
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (472)..(1389)

<400> 3
 ttcttagagc aagaaaacag cagctcatgg ccatcaccag ctgtgaccag cagctcagaa 60
 agaatccgtg ggaaacggag ggccaaagcc ttgagatgga caaggcagaa gtcggtggag 120
 gaaggggagc caccaggtca gggggaaggt ccccggtcca ggccaactgc tgagtccacc 180
 gggctggagg ccacattccc caagaccaca cccttggtc aagctgatcc tgccgggggtg 240
 ggactccac caacaggggtg ggactgcctc ccctctgact gtacagcctc agctgcaggc 300
 tccagcacag atgatgtgga gctggccacg gagttcccag ccacagaggc ctgggagtgt 360
 gagctagaag gcctgctgga agagaggcct gccctgtgcc tgtccccgca ggccccattt 420
 cccaagctgg gctgggatga cgaactgcgg aaaccgcggc cccagatcta c atg cgc 477
 Met Arg
 1

ttc atg cag gag cac acc tgc tac gat gcc atg gca act agc tcc aag 525
 Phe Met Gln Glu His Thr Cys Tyr Asp Ala Met Ala Thr Ser Ser Lys
 5 10 15

cta gtc atc ttc gac acc atg ctg gag atc aag aag gcc ttc ttt gct Leu Val Ile Phe Asp Thr Met Leu Glu Ile Lys Lys Ala Phe Phe Ala 20 25 30	573
ctg gtg gcc aac ggt gtg cgg gca gcc cct cta tgg gac agc aag aag Leu Val Ala Asn Gly Val Arg Ala Ala Pro Leu Trp Asp Ser Lys Lys 35 40 45 50	621
cag agc ttt gtg ggg atg ctg acc atc act gac ttc atc ctg gtg ctg Gln Ser Phe Val Gly Met Leu Thr Ile Thr Asp Phe Ile Leu Val Leu 55 60 65	669
cat cgc tac tac agg tcc ccc ctg gtc cag atc tat gag att gaa caa His Arg Tyr Tyr Arg Ser Pro Leu Val Gln Ile Tyr Glu Ile Glu Gln 70 75 80	717
cat aag att gag acc tgg agg gag atc tac ctg caa ggc tgc ttc aag His Lys Ile Glu Thr Trp Arg Glu Ile Tyr Leu Gln Gly Cys Phe Lys 85 90 95	765
cct ctg gtc tcc atc tct cct aat gat agc ctg ttt gaa gct gtc tac Pro Leu Val Ser Ile Ser Pro Asn Asp Ser Leu Phe Glu Ala Val Tyr 100 105 110	813
acc ctc atc aag aac cgg atc cat cgc ctg cct gtt ctt gac ccg gtg Thr Leu Ile Lys Asn Arg Ile His Arg Leu Pro Val Leu Asp Pro Val 115 120 125 130	861
tca ggc aac gta ctc cac atc ctc aca cac aaa cgc ctg ctc aag ttc Ser Gly Asn Val Leu His Ile Leu Thr His Lys Arg Leu Leu Lys Phe 135 140 145	909
ctg cac atc ttt ggt tcc ctg ctg ccc cgg ccc tcc ttc ctc tac cgc Leu His Ile Phe Gly Ser Leu Leu Pro Arg Pro Ser Phe Leu Tyr Arg 150 155 160	957
act atc caa gat ttg ggc atc ggc aca ttc cga gac ttg gct gtg gtg Thr Ile Gln Asp Leu Gly Ile Gly Thr Phe Arg Asp Leu Ala Val Val 165 170 175	1005
ctg gag aca gca ccc atc ctg act gca ctg gac atc ttt gtg gac cgg Leu Glu Thr Ala Pro Ile Leu Thr Ala Leu Asp Ile Phe Val Asp Arg 180 185 190	1053
cgt gtg tct gca ctg cct gtg gtc aac gaa tgt ggt cag gtc gtg ggc Arg Val Ser Ala Leu Pro Val Val Asn Glu Cys Gly Gln Val Val Gly 195 200 205 210	1101
ctc tat tcc cgc ttt gat gtg att cac ctg gct gcc cag caa acc tac Leu Tyr Ser Arg Phe Asp Val Ile His Leu Ala Ala Gln Gln Thr Tyr 215 220 225	1149
aac cac ctg gac atg agt gtg gga gaa gcc ctg agg cag agg aca cta Asn His Leu Asp Met Ser Val Gly Glu Ala Leu Arg Gln Arg Thr Leu 230 235 240	1197
tgt ctg gag gga gtc ctt tcc tgc cag ccc cac gag agc ttg ggg gaa Cys Leu Glu Gly Val Leu Ser Cys Gln Pro His Glu Ser Leu Gly Glu 245 250 255	1245

gtg atc gac agg att gct cgg gag cag gta cac agg ctg gtg cta gtg 1293
 Val Ile Asp Arg Ile Ala Arg Glu Gln Val His Arg Leu Val Leu Val
 260 265 270

gac gag acc cag cat ctc ttg ggc gtg gtc tcc ctc tcc gac atc ctt 1341
 Asp Glu Thr Gln His Leu Leu Gly Val Val Ser Leu Ser Asp Ile Leu
 275 280 285 290

cag gca ctg gtg ctc agc cct gct ggc atc gat gcc ctc ggg gcc tga 1389
 Gln Ala Leu Val Leu Ser Pro Ala Gly Ile Asp Ala Leu Gly Ala
 295 300 305

gaagatctga gtcctcaatc ccaagccaac tgcacactgg aagccaatga aggaattgag 1449
 aacagcttca tttccccaac cccaatttgc tgggttcagct atgattcagg cttcttcagc 1509
 cttccaaaat tgcctttgcc ttactttgtgc tcccagaacc cttcggggcat gcccagtgc 1569
 ccatgggatg atgaaattaa ggagaacagc tgagtcaagc ttggaggtcc ctgaaccaga 1629
 ggcactagga ttaccccagg gccatctgtg ctocatgccc gcccatcccc ttgccgcctg 1689
 actgggtcgg atggccccag tgggttttagt cagggttctt ggattcctcg gtttctgggc 1749
 tacctatggc ttcagccttc agctcctggg agtcccagct gttgttccca gcaacgtcgc 1809
 cactgccctc ctactctcca ggctttgtca tttcaaggct gctgaaatgc tgcatttcag 1869
 gggccaccat ggagcagccg ttatttatag aactgcctgt tggaggtggg gagtctctcc 1929
 tccattcttg tccagaaaac tccttagctc tcgcagttag ccatgttctt agtctccagg 1989
 gatggatggc cttgtatatg gacccctgag aatgagcaat tgagaaaaca aaacaaaagg 2049
 aacaatccat gaacttagat tttattgggt tcaactcaaaa tgctgcagtc atttgacctg 2109

<210> 4

<211> 305

<212> PRT

<213> Homo sapiens

<400> 4

Met Arg Phe Met Gln Glu His Thr Cys Tyr Asp Ala Met Ala Thr Ser
 1 5 10 15

Ser Lys Leu Val Ile Phe Asp Thr Met Leu Glu Ile Lys Lys Ala Phe
 20 25 30

Phe Ala Leu Val Ala Asn Gly Val Arg Ala Ala Pro Leu Trp Asp Ser
 35 40 45

Lys Lys Gln Ser Phe Val Gly Met Leu Thr Ile Thr Asp Phe Ile Leu
 50 55 60

Val Leu His Arg Tyr Tyr Arg Ser Pro Leu Val Gln Ile Tyr Glu Ile
 65 70 75 80

Glu Gln His Lys Ile Glu Thr Trp Arg Glu Ile Tyr Leu Gln Gly Cys
 85 90 95

Phe Lys Pro Leu Val Ser Ile Ser Pro Asn Asp Ser Leu Phe Glu Ala
 100 105 110
 Val Tyr Thr Leu Ile Lys Asn Arg Ile His Arg Leu Pro Val Leu Asp
 115 120 125
 Pro Val Ser Gly Asn Val Leu His Ile Leu Thr His Lys Arg Leu Leu
 130 135 140
 Lys Phe Leu His Ile Phe Gly Ser Leu Leu Pro Arg Pro Ser Phe Leu
 145 150 155 160
 Tyr Arg Thr Ile Gln Asp Leu Gly Ile Gly Thr Phe Arg Asp Leu Ala
 165 170 175
 Val Val Leu Glu Thr Ala Pro Ile Leu Thr Ala Leu Asp Ile Phe Val
 180 185 190
 Asp Arg Arg Val Ser Ala Leu Pro Val Val Asn Glu Cys Gly Gln Val
 195 200 205
 Val Gly Leu Tyr Ser Arg Phe Asp Val Ile His Leu Ala Ala Gln Gln
 210 215 220
 Thr Tyr Asn His Leu Asp Met Ser Val Gly Glu Ala Leu Arg Gln Arg
 225 230 235 240
 Thr Leu Cys Leu Glu Gly Val Leu Ser Cys Gln Pro His Glu Ser Leu
 245 250 255
 Gly Glu Val Ile Asp Arg Ile Ala Arg Glu Gln Val His Arg Leu Val
 260 265 270
 Leu Val Asp Glu Thr Gln His Leu Leu Gly Val Val Ser Leu Ser Asp
 275 280 285
 Ile Leu Gln Ala Leu Val Leu Ser Pro Ala Gly Ile Asp Ala Leu Gly
 290 295 300
 Ala
 305

<210> 5
 <211> 20
 <212> DNA
 <213> Sus scrofa

<400> 5
 ggaatttcaa gtcagccaac

20

<210> 6
 <211> 20
 <212> DNA
 <213> Sus scrofa

<400> 6
 cttcaaaaga ccgtgctact

20

<210> 7
<211> 20
<212> DNA
<213> Sus scrofa

<400> 7
ctgggaacct ctatatgctg 20

<210> 8
<211> 20
<212> DNA
<213> Sus scrofa

<400> 8
tagggaaata caaatcacag 20

<210> 9
<211> 20
<212> DNA
<213> Sus scrofa

<400> 9
ctccagctca caggatgaca 20

<210> 10
<211> 26
<212> DNA
<213> Sus scrofa

<400> 10
gtttctgcag ctttagcatc tattcc 26

<210> 11
<211> 20
<212> DNA
<213> Sus scrofa

<400> 11
gaagtatcct gggctttctga 20

<210> 12
<211> 26
<212> DNA
<213> Sus scrofa

<400> 12
gtttctccag gtttccagac atccac 26

<210> 13
<211> 20
<212> DNA
<213> Sus scrofa

<400> 13

gcttctgtct gccctactt 20

<210> 14
<211> 26
<212> DNA
<213> Sus scrofa

<400> 14
gtttctaagt totactgtaa gacacc 26

<210> 15
<211> 20
<212> DNA
<213> Sus scrofa

<400> 15
ccaagctgtg gtggctgaat 20

<210> 16
<211> 20
<212> DNA
<213> Sus scrofa

<400> 16
cagcacagca gtgccaccta 20

<210> 17
<211> 19
<212> DNA
<213> Sus scrofa

<400> 17
caaactcttc taggcgtgt 19

<210> 18
<211> 26
<212> DNA
<213> Sus scrofa

<400> 18
gtttctggaa cttccatatg ccatgg 26

<210> 19
<211> 20
<212> DNA
<213> Sus scrofa

<400> 19
agggtggatg gtaggcttca 20

<210> 20
<211> 20
<212> DNA
<213> Sus scrofa

<400> 20
gtctcgctcc tgaaggaagt 20

<210> 21
<211> 20
<212> DNA
<213> Sus scrofa

<400> 21
agtcacgtgg ccatgctatc 20

<210> 22
<211> 20
<212> DNA
<213> Sus scrofa

<400> 22
ctcaactgga ttgagtcagt 20

<210> 23
<211> 20
<212> DNA
<213> Sus scrofa

<400> 23
ttggcgcaac tgttatttct 20

<210> 24
<211> 19
<212> DNA
<213> Sus scrofa

<400> 24
aggcaaagga agagcacag 19

<210> 25
<211> 18
<212> DNA
<213> Sus scrofa

<400> 25
agccgtgggc atcgttgg 18

<210> 26
<211> 21
<212> DNA
<213> Sus scrofa

<400> 26
agaaggagac agacagggcga 21

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☒ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☐ **FADED TEXT OR DRAWING**

☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)